document incorporate reference part portion registrant proxy statement annual meeting shareholder file day close iii registrant fiscal year proxy statement incorporate reference report reportitem business general segment business geographic area raw material patent trademark seasonality competition environment regulation employee human capital management available information risk factor unresolved staff comment property legal proceeding safety disclosure executive officer registrant market registrant common equity relate stockholder matter issuer purchase equity security reserve management discussion analysis result operation financial condition quantitative qualitative disclosure market risk financial statement supplementary data change disagreement accountant account financial disclosure control procedure information disclosure foreign jurisdiction prevent inspection iii director executive officer corporate governance executive compensation security ownership certain beneficial owner management relate stockholder matter certain relationship relate transaction director independence principal accountant fee service exhibit financial statement schedule summary signature exhibit index cautionary note forwardlooke statement annual report johnson johnsons publicly available document contain forwardlooke statement mean safe harbor provision united states private security litigation reform act management representatives johnson johnson subsidiaries company time time forwardlooke statement forwardlooke statement relate strictly historical current fact reflect management assumption view plan objective projection future forwardlooke statement identify use word plan expect anticipate estimate word similar meaning conjunction thing discussion future operation expect operating result financial performance impact plan acquisition disposition impact time restructuring initiative include associate cost saving benefit plan separation company consumer health business company strategy growth product development activity regulatory approval market position expenditure forwardlooke statement base current belief expectation assumption future event subject uncertainty risk change difficult predict outside company control investor realize underlying assumption prove inaccurate know unknown risk uncertainty materialize company actual result financial condition vary materially expectation projection express imply forwardlooke statement investor caution rely forwardlooke statement risk uncertainty include limited risk relate product development market success competition challenge uncertainty inherent innovation development new improved product technology company continue growth success depend include uncertainty clinical outcome additional analysis exist clinical datum obtain regulatory approval health plan coverage customer access initial continue commercial success challenge company ability obtain protect adequate patent intellectual property right new exist product technologies united states important market impact patent expiration typically follow introduction compete generic biosimilar product result revenue market share loss increasingly aggressive frequent challenge company patent competitor seek launch compete generic biosimilar product increase receptivity court united states patent trademark office decision maker challenge potentially result loss market exclusivity rapid decline sale relevant product soon expect competition research development new improved product process technology result product process obsolescence competition reach agreement party collaboration licensing development marketing agreement product technology competition base costeffectiveness product performance technological advance patent attain competitor allegation company product infringe patent intellectual property right party adversely affect company ability sell product question require payment money damage future royalty risk relate product liability litigation regulatory activity product efficacy safety concern base scientific evidence potentially result product withdrawal recall regulatory action united states food drug administration international counterpart decline sale reputational damage increase litigation expense share price impact impact include decline sale reputational damage significant litigation government action adverse company include product liability claim allegation relate pharmaceutical marketing practice contracting strategy impact adverse judgment settlement adequacy reserve relate legal proceeding include patent litigation product liability personal injury claim security class action government investigation employment legal proceeding increase scrutiny healthcare industry government agency state attorney general result investigation prosecution carry risk significant civil criminal penalty include limited debarment government business failure meet compliance obligation compliance agreement government government agency result significant sanction potential change applicable law regulation affect united states international operation include relate approval new product license patent right sale promotion healthcare product access reimbursement pricing healthcare product service environmental protection source raw material compliance local regulation law restrict company ability manufacture sell product relevant market include requirement comply medical device report regulation requirement european union medical device regulation change domestic international tax law regulation increase audit scrutiny tax authority world exposure additional tax liability potentially excess exist reserve issuance new revise accounting standard financial accounting standard board regulation securities exchange commission risk relate company strategic initiative healthcare market trend plan separation company consumer health business pricing pressure result trend healthcare cost containment include continued consolidation healthcare provider market participant trend manage care shift government increasingly primary payer healthcare expense significant new entrant healthcare market seek reduce cost government pressure company voluntarily reduce cost price increase restrict spend pattern individual institutional governmental purchaser healthcare product service economic hardship budgetary constraint challenge company ability realize strategy growth include externally source innovation development collaboration strategic acquisition license marketing agreement potential heighten cost external arrangement competitive pressure potential expect strategic benefit opportunity plan complete acquisition divestiture company realize long realize expect potential expect benefit opportunity relate past ongoing restructure action realize long realize expect company ability consummate plan separation company consumer health business timely basis company ability successfully separate company consumer health business realize anticipate benefit plan separation new consumer health company ability succeed standalone publicly trade company risk relate economic condition financial market operate internationally risk associate global operation company customer supplier include foreign government country company operate impact inflation fluctuation interest rate currency exchange rate potential effect fluctuation revenue expense result margin potential change exportimport trade law regulation policy united states country include increase trade restriction tariff potential drug reimportation legislation impact international operation financial instability international economy sovereign risk possible imposition governmental control restrictive economic policy unstable international government legal system impact global public health crisis pandemic include novel coronavirus covid pandemic change global climate extreme weather natural disaster affect demand company product service cause disruption manufacture distribution network alter availability good service supply chain affect overall design integrity company product operation impact armed conflict terrorist attack united states part world include social economic disruption instability financial market risk relate supply chain operation difficulty delay manufacture internally thirdparty provider supply chain lead voluntary involuntary business interruption shutdown product shortage withdrawal suspension product market potential regulatory action interruption breach company information technology system company vendor result reputational competitive operational business harm financial cost regulatory action reliance global supply chain production distribution process complex subject increase regulatory requirement adversely affect supply source pricing material company product potential expect benefit opportunitie related restructuring action contemplate global supply chain realize long realize expect include require approval applicable regulatory authority investor carefully read risk factor describe item annual report description certain risk thing cause company actual result differ materially express forwardlooke statement investor understand possible predict identify factor consider risk describe item complete statement potential risk uncertainty company undertake publicly update forwardlooke statement time time result new information future event developmentspart item business general johnson johnson subsidiaries company approximately employee worldwide engage research development manufacture sale broad range product healthcare field johnson johnson hold company operate company conduct business virtually country world company primary focus product relate human health wellbee johnson johnson incorporate state new jersey executive committee johnson johnson principal management group responsible strategic operation allocation resource company committee oversee coordinate activity company business segment consumer health pharmaceutical medical device strategic parameter provide committee senior management group international operating company responsible strategic plan daytoday operation company subsidiary business segment limited exception manage resident country locate segment business company organize business segment consumer health pharmaceutical medical device additional information require item incorporate reference narrative tabular description segment operate result item management discussion analysis result operation financial condition report note segment business geographic area note consolidated financial statement include item report consumer health consumer health segment include broad range product focus personal healthcare skin healthbeauty overthecounter medicine baby care oral care womens health wound care market major brand skin healthbeauty include aveeno clean clear cilabo neutrogena ogx product line overthecounter otc medicine include broad family tylenol acetaminophen product sudafe cold flu allergy product benadryl zyrtec allergy product motrin ibuprofen product nicorette smoking cessation product outside zarbee products inspire nature pepcid line acid reflux product baby care include johnson aveeno baby line product oral care include listerine product line major brand women health outside north america stayfree carefree sanitary pad tampon brands wound care brand include bandaid brand adhesive bandage neosporin aid product line product market general public sell online ecommerce retail outlet distributor world november company announce intention separate company consumer health business intention create new publicly trade company company target completion plan separation month initial announcement pharmaceutical pharmaceutical segment focus therapeutic area immunology rheumatoid arthritis psoriatic arthritis inflammatory bowel disease psoriasis infectious disease hivaid covid neuroscience mood disorder neurodegenerative disorder schizophrenia oncology prostate cancer hematologic malignancy lung cancer bladder cancer cardiovascular metabolism thrombosis diabete macular degeneration pulmonary hypertension pulmonary arterial hypertension medicine segment distribute directly retailer wholesaler distributor hospitals healthcare professional prescription use key product pharmaceutical segment include remicade infliximab treatment number immunemediate inflammatory disease simponi golimumab subcutaneous treatment adult moderate severe rheumatoid arthritis active psoriatic arthritis active ankylose spondylitis moderately active severely active ulcerative colitis simponi aria golimumab intravenous treatment adult moderate severe rheumatoid arthritis active psoriatic arthritis active ankylose spondylitis active polyarticular juvenile idiopathic arthritis pjia people year age old stelara ustekinumab treatment adult child moderate severe plaque psoriasis adult active psoriatic arthritis adult moderately severely active crohn disease treatment moderately severely active ulcerative colitis tremfya guselkumab treatment adult moderate severe plaque psoriasis active psoriatic arthritis janssen covid vaccine authorize use emergency use authorization eua active immunization prevent coronavirus disease covid cause severe acute respiratory syndrome coronavirus sarscov individual year age old edurant rilpivirine prezista darunavir prezcobix rezolsta darunavircobicistat antiretroviral medicine treatment human immunodeficiency virus hiv combination antiretroviral product symtuza darunavircobicistatemtricitabinetenofovir alafenamide oncedaily single tablet regimen treatment hiv concerta methylphenidate hcl extendedrelease tablet cii treatment attention deficit hyperactivity disorder invega sustenna xeplion paliperidone palmitate treatment schizophrenia schizoaffective disorder adult invega trinza trevicta paliperidone palmitate treatment schizophrenia patient adequately treat invega sustenna month risperdal consta risperidone longacte injection treatment schizophrenia maintenance treatment bipolar disorder adult zytiga abiraterone acetate treatment patient prostate cancer erleada apalutamide nextgeneration androgen receptor inhibitor treatment patient prostate cancer imbruvica ibrutinib treatment certain bcell malignancy blood cancer chronic graft versus host disease darzalex daratumumab treatment multiple myeloma darzalex faspro daratumumab hyaluronidase fihj treatment multiple myeloma light chain amyloidosis procrit eprex epoetin alfa treatment chemotherapyinduce anemia patient chronic kidney disease xarelto rivaroxaban oral anticoagulant prevention deep vein thrombosis dvt lead pulmonary embolism patient undergo hip knee replacement surgery reduce risk stroke systemic embolism patient nonvalvular atrial fibrillation treatment reduction risk recurrence dvt reduce risk major cardiovascular event patient coronary artery disease cad peripheral artery disease pad treatment secondary prevention thromboembolism pediatric patient thromboprophylaxis pediatric patient follow fontan procedure invokana canagliflozin treatment adult type diabete invokamet vokanamet canagliflozinmetformin hcl combination therapy fix dose canagliflozin metformin hydrochloride treatment adult type diabete invokamet canagliflozinmetformin hydrochloride extendedrelease oncedaily fixeddose combination therapy canagliflozin metformin hydrochloride extendedrelease treatment adult type diabete opsumit macitentan monotherapy combination indicate longterm treatment pulmonary arterial hypertension pah uptravi selexipag approve oral intravenous selective receptor agonist target prostacyclin pathway pah medicine develop collaboration strategic partner license company maintain active lifecycle development program medical device medical device segment include broad range product interventional solution orthopaedic surgery vision field medical device interventional solution include electrophysiology product biosense webster treat cardiovascular disease neurovascular care cerenovus treat hemorrhagic ischemic stroke orthopaedic portfolio depuy synthe comprise product support hip knee trauma spine sport surgery portfolio include advanced general surgery offering ethicon solution focus breast aesthetic mentor ear nose throat acclarent procedure johnson johnson vision products acuvue brand disposable contact lense ophthalmic product relate cataract laser refractive surgery product distribute wholesaler hospital retailer predominantly professional field physician nurse hospital eye care professional clinic begin fiscal quarter medical device segment refer medtech segment geographic areas johnson johnson subsidiaries company approximately employee worldwide engage research development manufacture sale broad range product healthcare field company conduct business virtually country world primary focus product relate human health wellbeing product sell international business include describe segment business consumer health pharmaceutical medical device principal market product method distribution international business vary country culture product sell international business include develop subsidiary abroad investment activity country outside subject high risk comparable activity investment commercial climate influence financial instability international economy restrictive economic policy political legal system uncertaintie raw material raw material essential company business generally readily available multiple source exception temporary unavailability raw material likely material adverse effect financial result company patent company subsidiary practice obtain patent protection product process possible license significant number patent country relate product product use formulation manufacturing process aggregate believe material importance company operation business company subsidiary face patent challenge thirdpartie include challenge seek manufacture market generic biosimilar version company key pharmaceutical product prior expiration applicable patent cover product significant legal proceeding claim involve company patent intellectual property describe note legal proceeding intellectual property note consolidated financial statement include item report sale company large product stelara ustekinumab account approximately company total revenue fiscal accordingly patent relate product believe material company janssen biotech inc whollyowne subsidiary johnson johnson own patent specifically relate stelara late expiring united states composition matter patent expire late expire european composition matter patent expire sale company second large product collectively darzalex daratumumab darzalex faspro daratumumab hyaluronidasefihj account approximately company total revenue fiscal accordingly patent relate product believe material company genmab own patent family relate darzalex janssen biotech inc exclusive license patent family patent family expire united states late expiring license european patent expire janssen biotech inc own separate patent portfolio relate darzalex faspro trademark company subsidiary practice sell product trademark obtain protection trademark available mean trademark protect registration country product market company consider trademark aggregate material importance operation business seasonality worldwide sale reflect significant degree seasonality spend heavy fourth quarter year quarter reflect increase spending decision principally advertise research development activity competition product line company subsidiary compete company locally globally competition exist product line regard number size compete company involve competition research internally externally source involve development improvement new exist product process particularly significant development new innovative product protect underlie intellectual property company product portfolio important company success area business competitive environment require substantial investment continue research addition development maintenance customer demand company consumer product involve significant expenditure advertising promotion environment company subject variety international environmental protection measure company believe operation comply material respect applicable environmental law regulation companys compliance requirement expect material effect capital expenditure cash flow earning competitive position regulation company business subject vary degree governmental regulation country operation conduct general trend increasingly stringent regulation enforcement company subject costly complex foreign law governmental regulation adverse regulatory action materially adversely affect company financial condition business operation drug device cosmetic industry long subject regulation federal state agency primarily product safety efficacy manufacturing advertising labeling safety report exercise broad regulatory power food drug administration fda continue result increase amount test documentation require fda approval new drug device correspond increase expense product introduction similar trend evident major market outside new medical device regulatory framework new privacy regulation europe country example increase regulation regulatory agency purview company operate administrative power subject action product withdrawal recall seizure product civil criminal sanction case company subsidiary deem advisable initiate product recall fda regulatory agency globe increase enforcement activity fdawere conclude compliance applicable law regulation drug medical device ineffective pose unreasonable health risk fda ban product detain seize adulterate misbrande product order recall repair replacement refund product refuse grant pende application marketing authorization require certificate foreign government export andor require notify health professional product present unreasonable risk substantial harm public health fda assess civil criminal penalty officer employee impose operating restriction companywide basis enjoin andor restrain certain conduct result violation applicable law fda recommend prosecution department justice adverse regulatory action depend magnitude restrict effectively market selling product limit ability obtain future clearance approval result substantial modification business practice operation equivalent enforcement mechanism exist different country conduct business cost human healthcare continue subject study investigation regulation governmental agency legislative body world attention focus state regulatory agency congress drug price profit program encourage doctor write prescription particular drug recommend use purchase particular medical device law regulation enact require adherence strict compliance standard prevent fraud abuse healthcare industry increase focus interaction financial relationship healthcare company healthcare provider transparency law regulation require disclosure payment transfer value physician teach hospital begin disclosure certain nonphysician practitioner federal foreign law govern international business practice require strict compliance antibribery standard certain prohibition respect payment foreign government official payer potent force market place increase attention pay drug medical device price appropriate drug medical device utilization quality cost healthcare generally government actor continue effort repeal modify invalidate provision patient protection affordable care act aca pass example federal legislation repeal acas individual mandate tax penalty tax generous employersponsored healthcare plan center medicare medicaid services cms begin permit state impose work requirement person cover medicaid expansion plan certain federal subsidy insurer end certain shortterm insurance plan offer array aca benefit allow extend duration change challenge court longterm impact remain uncertain aca subject judicial challenge november supreme court hear argument texas azar challenge constitutionality aca pende resolution litigation aca individual mandate buy health insurance remain effect government continue propose implement change medicare benefit include size manufacturer discount coverage gap catastrophic phase benefit number additional bill pende congress healthcare reform proposal state level affect drug pricing medicare medicaid program change federal landscape positive negative impact healthcare industry remain uncertain provision federal law potential modification repeal law ultimately affect industry addition business practice healthcare industry come increase scrutiny particularly government agency state attorney general result investigation prosecution carry risk significant civil criminal penalty company rely global supply chain production distribution process complex subject increase regulatory requirement face unexpected change result covid pandemic brexit affect source supply pricing material company product process subject complex lengthy regulatory approval global regulatory landscape subject change covid pandemic continue affect global economy fda health authority shift resource priority meet challenge present pandemic pandemicrelate disruption negatively impact process regulatory submission slow agency review times necessary approval clearance new drug device duration severity covid pandemic unpredictable difficult assess employee human capital management january january number employee approximately employee fulltime equivalent fte position employee define individual work fulltime parttime exclude fix term employee intern coop employee employee datum include population recently acquire company individual longterm disability exclude contingent worker contractor subcontractor exclude fte represent total number fulltime equivalent position reflect total number individual employee work parttime strategy company believe employee critical continued success essential element longterm strategy management responsible ensuring policy process reflect reinforce company desire corporate culture include policy process relate strategy risk management ethic compliance company human capital management strategy build fundamental focus area attract recruit good talent develop retain talent empower inspire talent underpin focus area ongoing effort cultivate foster culture build diversity equity inclusion dei innovation health wellbeing safety company employee encourage succeed professionally personally help company achieve business goal culture employee engagement johnson johnson employees guide credo set forth company responsibility patient consumer customer healthcare professional employee communitie shareholder employee worldwide guide company code business conduct set basic requirement business conduct serve foundation company policy procedure guideline provide additional guidance expect employee behavior market operate company conduct global survey offer employee ability provide feedback valuable insight help address potential human resource risk identify opportunity improve global employee country participate voice survey offer language growth development continue lead change healthcare landscape crucial company continue attract retaintop talent company believe employee equip right knowledge skill provide opportunity grow develop career accordingly professional development program educational resource available employee company objective foster learning culture help shape person unique career path create robust pipeline talent deliver company longterm strategy furtherance objective company deploy global approach ensure development regardless career journey employee manager job category take advantage career opportunity move function country business segment line include upward promotion lateral transfer exclude employee research development organization company voluntary turnover rate diversity equity inclusion dei company commit workplace diversity cultivate foster advance culture equity inclusion enable employee perform good fundamental company continued success company dei vision change world company dei strategy focus pillar reflect strategic priority identify enable company address challenge opportunity present evolve understand diversity accelerate company effort advance culture inclusion innovation build diverse workforce future enhance business result reputation company dei strategy guide internal external insight global good practice continual employee feedback remind company diversity change location inclusion compensation benefit company total reward philosophy company offer competitive compensation benefit attract retain talent company commit fairness equitable treatment compensation benefit employee level company observe legal minimum wage provision exceed possible company total reward offering include array program support employee financial physical mental wellbeing include annual performance incentive opportunitie pension retirement saving program health welfare benefit pay time leave program flexible work schedule employee assistance program health wellness safety company investment employee health wellbeing safety build conviction advance health humanity start advance health employee right awareness focus practice tool company ensure employee world temporary contractor visitor company site work safely company continuously expand health wellbeing program company globe incorporate new thinking technology offering bestinclass help employee achieve personal health goal program practice company advance total healthphysical mental emotional financialhelp ensure employee health protection emerge health risk safety covid pandemic response protect support employee covid pandemic continue priority approach include keep employee inform local covid transmission rate correspond risk level promote health safety employee workplace robust layer protection enhance cleaning access cleaning supply personal protective equipment support employee pay continuity benefit wellbee tool recognize extraordinary employee contribution work community recognition new way work initiate flex hybrid model empower officebase employee find right productivity balance inperson remote work model allow work happen seamlessly variety workplace enable array enhance collaboration tool technology optimize productivity connection flex roll fourth quarter globally continue deployment protocol requirement relate covid pandemic allow company evaluate flexible work strategy onsite workforce virtual onboarding training help employee balance personal professional life continue enhance benefit offering access wellness tool onsite vaccine clinic mental health support resource delivery athome testing kit addition covid vaccine broadly distribute administer include develop johnson johnson adopt policy puerto rico certain country require proof vaccination johnson johnson employees contingent worker order return site permit local law regulation puerto rico requirement take effect october process establish grant accommodation medical religious need select manufacturing distributionemployee contractor puerto rico certain additional country adopt similar policy early available information company main corporate website address wwwjnjcom company sec filing available company website wwwinvestorjnjcomseccfm soon reasonably practicable electronically file furnish sec sec filing available secs website wwwsecgov investor public note company announce information wwwfactsaboutourprescriptionopioidscom wwwfactsabouttalccom wwwltlmanagementinformationcom use website communicate investor public product litigation matter possible information post website deem material information encourage investor interested company review information post website conjunction wwwjnjcom company sec filing press release public conference call webcast addition amend restate certificate incorporation bylaw write charter audit committee compensation benefit committee nominate corporate governance committee regulatory compliance committee science technology sustainability committee special committee board director company principle corporate governance code business conduct employee code business conduct ethic member board director executive officer corporate governance material available wwwinvestorjnjcomgovcfm company website provide charge shareholder submit write request provide information wwwjnjcom wwwfactsaboutourprescriptionopioidscom wwwfactsabouttalccom wwwltlmanagementinformationcom deem report incorporate filing company make sec item risk factor investment company common stock debt security involve risk uncertainty company seek identify manage mitigate risk business uncertainty risk difficult predict outside company control eliminate addition information report company filing sec investor consider carefully factor set forth investor aware possible predict identify factor follow mean complete discussion potential risk uncertainty know unknown risk uncertainty materialize company business result operation financial condition adversely affect potentially material way risk relate business industry operation company business operate highly competitive product market competitive pressure adversely affect company earning company face substantial competition operate segment geographic market company business compete company size basis costeffectiveness technological innovation intellectual property right product performance real perceive product advantage price availability rate reimbursement company compete market participant secure right acquisition collaboration license agreement party competition right product candidate technology result significant investment acquisition cost onerous agreement term company competitor development effective costly product andor ability secure patent intellectual property right successfully market product ahead company negatively impact sale company exist product ability bring new product market despite significant prior investment relate product development company pharmaceutical business loss patent exclusivity product follow substantial reduction sale competitor gain regulatory approval generic compete product enter market similar competition trigger loss exclusivity biological product company medical device business technological innovation product quality reputation customer service especially important competitiveness development company new improved product process technology threaten company product technology desirable economical obsolete company consumer health business face intense competition brand product retailer privatelabel brand company fail sufficiently differentiate market brand consumer product adversely affect revenue profitability product interruption delay manufacture operation adversely affect company business sale reputation company manufacture product require timely delivery sufficient amount complex highquality component material company subsidiary operate manufacturing facility source thousand supplier world company past future face unanticipated interruption delay manufacture internal external supply chain manufacturing disruption occur reason include regulatory action production quality deviation safety issue labor dispute labor shortage sitespecific incident fire natural disaster hurricane severe weather event raw material shortage political unrest terrorist attack epidemic pandemic delay difficulty manufacturing result product shortage decline sale reputational impact significant remediation relate cost associate address shortage company rely party manufacture certain product failure loss thirdparty manufacturer result delay increase cost adversely affect business company rely party manufacture certain product depend thirdparty manufacturer allocate portion manufacturing capacity sufficient meet need produce product acceptable quality acceptable manufacturing yield deliver product timely basis acceptable price guarantee thirdparty manufacturer able meet nearterm longterm manufacturing requirement result lose sale adverse effect business risk associate reliance party manufacture product include reliance party regulatory compliance quality assurance misappropriation company intellectual property limit ability manageour inventory possible breach manufacturing agreement party possible termination nonrenewal manufacturing agreement party time costly inconvenient thirdparty manufacturer suffer damage facility lose benefit material agreement experience power outage encounter financial difficulty unable secure necessary raw material supplier suffer reduction efficiency company experience significant business disruption event disruption company need seek source qualified thirdparty manufacturer likely result delay increase cost affect business adversely counterfeit version product harm patient negative impact revenue earning reputation business industry continues challenge vulnerability distribution channel illegal counterfeiting presence counterfeit product grow number market internet party illegally distribute sell counterfeit version product meet rigorous manufacturing testing standard distributor patient counterfeit product visually indistinguishable authentic version counterfeit medicine pose risk patient health safety condition manufacture unregulate unlicensed uninspected unsanitary site lack regulation content industry failure mitigate threat counterfeit medicine adversely impact business reputation impact patient confidence authentic product potentially result lose sale product recall increase threat litigation addition diversion product authorize market channel result reduced revenue negatively affect profitability covid pandemic adversely impact certain aspect company business cause disruption future impact company business result operation financial condition subject risk associate global health crisis epidemic pandemic include global outbreak coronavirus variant covid covid pandemic adversely impact expect continue adversely impact certain aspect company business result operation financial condition include low sale reduce customer demand usage certain product spread covid cause company modify business practice include institute remote work company employee company action require government authority company determine good interest patient customer employee business partner company continue monitor situation robust business continuity plan place global supply chain network help mitigate impact covid effort completely prevent business adversely affect future impact remain uncertain country begin begin reopen economy extent covid impact company future operation depend factor predict confidence include duration outbreak impact variant resurgence covid result imposition new mandate prolong restrictive measure implement order control spread disease continue global spread covid adversely impact company operation include thing manufacture operation supply chain include thirdparty supplier sale marketing clinical trial operation factor adversely affect company business financial result global economic condition generally face uncertainty relate covid vaccine include uncertainty relate risk continue development program successful commercially viable receive approval regulatory authority risk associate clinical trial realworld datum include analysis efficacy safety durability risk datum subject differ interpretation assessment include peer reviewpublication process scientific community generally national immunization technical advisory group nitag regulatory authority disruption relationship thirdparty supplier external manufacturer risk company produce superior competitive product risk demand product develop long exist risk relate availability raw material manufacture product risk able recoup cost associate manufacturing effort risk associate change way approach provide additional research fund potential drug development relate covid risk able create scale manufacturing capacity timely basis continue experience manufacturing delay manufacturing site activate access logistic supply channel commensurate global demand potential approve vaccine product candidate negatively impact ability supply estimate number dose vaccine project time period indicate challenge risk associate pace vaccine development program pricing access challenge product include addition extent covid pandemic adversely affect business financial result theeffect heighten risk describe risk factor section incorporate reference nclude risk relate company effective tax rate result change consumption change law relate supply company product give development concern covid pandemic constantly evolve additional impact risk arise include litigation presently know company risk relate government regulation legal proceeding global sale company pharmaceutical medical device segment negatively impact healthcare reform increase pricing pressure sale companys pharmaceutical medical device product significantly affect reimbursement thirdparty payer government healthcare program private insurance plan manage care organization effort contain healthcare cost payer put downward pressure price product reimburse increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary continued consolidation healthcare provider result pricing pressure addition increase political scrutiny result additional pricing pressure outside numerous major market include united kingdom japan china pervasive government involvement funding healthcare regard directly indirectly impose price control limit access reimbursement company product reduce value intellectual property protection company subject significant legal proceeding result significant expense fine reputational damage ordinary course business johnson johnson subsidiary subject numerous claim lawsuit involve issue product liability patent dispute claim product sale marketing pricing practice violate antitrust unfair trade practice andor consumer protection law company significant legal proceeding describe note legal proceeding note consolidated financial statement include item report litigation general security derivative action class action multidistrict litigation particular expensive disruptive matter include thousand plaintiff involve party seek large andor indeterminate amount include punitive exemplary damage remain unresolved year example company defendant numerous lawsuit arise use body powder contain talc primarily johnson baby powder company sale manufacturing marketing opioid company believe substantial defense matter feasible predict ultimate outcome litigation company future require pay significant amount result settlement judgment matter potentially excess accrual include matter company hold jointly severally liable defendant resolution increase accrual matter report period material adverse effect company result operation cash flow period company purchase thirdparty product liability insurance company utilize wholly own captive insurance company subject certain limit product reliability safety effectiveness concern significant negative impact sale result operation lead litigation cause reputational damage concern product safety raise internally litigant regulator consumer advocate base scientific evidence result safety alert product recall governmental investigation regulatory action food drug administration counterpart country private claim lawsuit payment fine settlement decline sale reputational damage circumstance result damage brand image brand equity consumer trust company product product recall past future prompt government investigation inspection shutdown manufacture facility continue product shortage relate sale decline significant remediation cost reputational damage possible civil penalty criminal prosecution company face significant regulatory scrutiny impose significant compliance cost expose company government investigation legal action penalty like company healthcare industry company subject extensive regulation investigation legal action national state local government agency country operate regulatory issue compliance current good manufacturing practice cgmp comparable quality regulation foreign country manufacturer drug device consumer product lead fine penalty product recall product shortage interruption production delay new product approval litigation addition marketing pricing sale company product subject regulation investigation legal action include federal food drug cosmetic act medicaid rebate program federal state false claim act state unfair trade practice act consumer protection law scrutiny healthcare industry business practice government agency state attorney general result investigation prosecution carry risk significant civil criminal penalty include limited debarment participation government healthcare program debarment materialadverse effect company business result operation significant current investigation litigation bring government agency describe note legal proceedingsgovernment proceeding note consolidated financial statement include item report change tax law exposure additional tax liability negatively impact company operating result change tax law regulation world include lead organization economic cooperation development negatively impact company effective tax rate result operation change statutory tax rate certain international tax provision country result revaluation company defer tax asset liability relate particular jurisdiction period new tax law enact change result expense benefit record company consolidate statement earning company closely monitor proposal arise country operate change tax law regulation occur time related expense benefit record material fiscal quarter year law change enact note income taxis note consolidated financial statement include item report additional information company conduct business file tax return numerous country address tax audits dispute tax authority connection government initiative company require disclose information tax authority operation world lead great audit scrutiny profit earn country company regularly assess likely outcome tax audits dispute determine appropriateness tax reserve tax authority position tax treatment contrary company expectation result tax liability excess reserve risk related intellectual property company face increase challenge intellectual property right central business company own license significant number patent proprietary right relate product manufacturing process right essential company business materially important company result operation public policy outside increasingly unfavorable intellectual property right company certain obtain adequate patent protection new product technologies united states important market protection grant long originally anticipate competitor routinely challenge validity extent company own licensed patent proprietary right litigation interference opposition proceeding inter part review ipr proceedings united states patent trademark office uspto proceeding absorb resource protract unpredictable addition challenge company product infringe patent party result injunction andor need pay past damage future royalty adversely affect competitive position sale product question company face increase patent challenge party seek manufacture market generic biosimilar version company key pharmaceutical product prior expiration applicable patent cover product manufacturer generic version innovative human pharmaceutical product challenge validity claim noninfringement innovator product abbreviate new drug application anda process fda relate anda litigation biologic price competition innovation act bpcia enact create new regulatory pathway approval fda biosimilar alternative innovator develop biological product create mechanism biosimilar applicant challenge patent innovator biologics ipr process uspto competitor challenge patent assert litigation event company successful defend patent challenge atrisk launch generic biosimilar firm product company lose major portion revenue reference product short period time current legal proceeding involve company patent intellectual property right describe note legal proceedingsintellectual property note consolidated financial statement include item report risk relate product development regulatory approval commercializationsignificant challenge delay company innovation development new product technology indication adverse impact company longterm success company continue growth success depend ability innovate develop new differentiate product service address evolve healthcare need patient provider consumer development successful product technology necessary offset revenue loss company exist product lose market share factor competition loss patent exclusivity new product introduce past year account approximately sale company certain able develop license acquire company product technology particular product candidate grant regulatory approval approve product commercially successful company pursue product development internal research development collaboration acquisition joint venture license arrangement party context develop new product particularly pharmaceutical biotechnology product medical device require significant investment resource year biopharmaceutical research development program result commercially viable product process depend factor include ability discern patient healthcare provider future need develop promise new compound strategy technology achieve successful clinical trial result secure effective intellectual property protection obtain regulatory approval timely basis reach market successfully differentiate company product compete product approach treatment new product enhancement exist product accept quickly significantly marketplace product price competition change customer preference healthcare purchasing pattern resistance healthcare provider uncertainty thirdparty reimbursement follow initial regulatory approval success product adversely impact safety efficacy finding large realworld patient population market entry competitive product risk relate financial economic market condition company face variety financial economic legal social political risk associate conduct business internationally company extensive operation business activity world accompany certain financial economic legal social political risk include list foreign currency exchange fiscal approximately company sale occur outside approximately europe western hemisphere exclude asiapacific africa region change nonus currency relative dollar impact company revenue expense company use financial instrument mitigate impact fluctuation currency exchange rate cash flow unhedged exposure continue subject currency fluctuation addition weaken strengthen dollar result significant favorable unfavorable translation effect operating result company nonus business activity translate dollar inflation currency devaluation risk company face challenge maintain profitability operation economy experience high inflation rate company account operation argentina venezuela highly inflationary prior threeyear cumulative inflation rate surpass company strive maintain profit margin area cost reduction program productivity improvement periodic price increase experience operating loss result continued inflation addition impact currency devaluation country experience high inflation rate significant currency exchange fluctuation negatively impact company operate result illegal importation pharmaceutical product illegal importation pharmaceutical product country government price control market dynamic result low price adversely affect company sale profitability country company operate exception limited quantity prescription drug personal use foreign import pharmaceutical product illegal current law volume illegal import continue rise ability patient customer obtain lowerprice import grow significantly antibribery regulation company subject federal foreign law govern international business practice respect payment government official law include foreign corrupt practice act fcpa prohibit publicly trade company promise offering give value foreign official corrupt intent influence foreign official purpose help company obtain retainbusiness gain improper advantage company business heavily regulate involve significant interaction foreign official country outside healthcare provider prescribe human pharmaceutical employ government purchaser human pharmaceutical government entity company interaction prescriber purchaser subject regulation fcpa addition application enforcement fcpa jurisdiction company operate law regulation include bribery act aim prevent penalize corrupt anticompetitive behavior enforcement activity law subject company additional administrative legal proceeding action include claim civil penalty criminal sanction administrative remedy include exclusion healthcare program financial economic legal social political risk risk inherent conduct business globally include local regional economic environment policy market serve include interest rate monetary policy inflation economic growth recession commodity price currency control limitation ability expatriate cash protective economic policy take government trade protection measure importexport licensing requirement compliance local regulation law include country regulatory requirement restrict company ability manufacture sell product relevant market diminish protection intellectual property contractual right certain jurisdiction potential nationalization expropriation company foreign asset political social upheaval economic instability repression human right issue geopolitical event include natural disaster disruption market war armed conflict terrorism epidemic pandemic failure maintain satisfactory credit rating adversely affect liquidity capital position borrowing cost access capital market currently maintain investment grade credit rating moodys investor service standard poor rating service rating agency routinely evaluate rating longterm shortterm debt base number factor downgrade credit rating credit rating agency result action factor control increase cost borrowing indebtedness incur reduce market capacity commercial paper require post additional collateral derivative contract assurance able maintain credit rating additional actual anticipate change downgrade credit rating include announcement rating review downgrade negative impact liquidity capital position access capital market risk relate planned separation consumer health business plan separation company consumer health business complete term timeline currently contemplate achieve expect result november company announce intention separate company consumer health business intention create new publicly trade company plan separation intend qualify taxfree transaction federal income tax purpose company target completion plan separation month initial announcement completion plan separation subject satisfaction certain condition include consultation work council employee representative body require final approval company board director receipt favorable opinion internal revenue service irs ruling respect taxfree nature transaction receipt regulatory approval assurance ultimate timing plan separation separation complete unanticipated development delay prevent adversely affect plan separation include limited disruption general financial market condition potential problem delay obtain regulatory tax approval clearance cost complete plan separation significant addition company unable achieve strategic financial benefit expect achieve plan separation company consumer health business company incur significant expense connection plan separation addition company able achieve strategic financial benefit expect result plan separation anticipate benefit plan separation base number assumption prove incorrectfollowe plan separation price share company common stock fluctuate significantly company predict effect plan separation trading price share common stock market value share common stock equal great market value share common stock prior plan separation addition price company common stock volatile time plan separation plan separation result substantial tax liability company intend obtain opinion tax advisor rule irs taxfree nature plan separation internal revenue code amend opinion ruling base thing factual assumption representation company new consumer health company past future conduct company respective business matter assumption representation inaccurate incomplete reliance opinion ruling jeopardize subsequent plan separation determine transaction qualify taxfree treatment federal income tax purpose result tax liability company shareholder substantial plan separation qualify taxfree treatment country world result trigger substantial tax liability company risk business depend ability recruit retain talente highly skilled employee diverse workforce continue growth require recruit retain talented employee represent diverse background experience skill set market highly skilled worker leader industry extremely competitive ability compete depend ability hire develop motivate highly skilled personnel area organization maintain brand reputation diverse equitable inclusive work environment enable attract talent successful recruiting effort retain highly skilled worker key leader ability develop deliver successful product service adversely affect addition effective succession plan important longterm success unsuccessful implementation succession plan failure ensure effective transfer knowledge smooth transition involve key employee adversely affect business financial condition result operation climate change legal regulatory market measure address climate change negatively affect business result operation climate change result increase concentration carbon dioxide greenhouse gas atmosphere present risk operation include adverse impact global temperature weather pattern frequency severity extreme weather natural disaster natural disaster extreme weather condition hurricane tornado earthquake wildfire flooding pose physical risk facility disrupt operation supply chain impact change climate water resource result water scarcity limit ability access sufficient highquality water certain location increase operational cost concern climate change result new additional legal regulatory requirement design reduce greenhouse gas emission andor mitigate effect climate change environment law regulation stringent current legal regulatory obligation experience disruption increase cost associate source manufacture distribution product adversely affect business result operation financial condition impact climate change influence customer preference failure provide climatefriendly product potentially result loss market share information security incident include cybersecurity breach negative impact company business reputation meet business objective company rely internal information technology system network party vendor process store sensitive datum include confidential research business plan financial information intellectual property personal datum subject legal protection ensure continuity company supply chain extensive information security cybersecurity threat affect company globally pose risk security availability system network confidentiality integrity availability company sensitive datum company continually assess threat make investment increase internal protection detection response capability ensure company thirdparty provider require capabilitiesand control address risk date company experience material impact business operation result information cybersecurity attack frequently change attack technique increase volume sophistication attack potential company adversely impact impact result reputational competitive operational business harm financial cost regulatory action company maintain cybersecurity insurance event information security cyber incident coverage sufficient cover financial legal business reputational loss breach privacy law unauthorized access loss misuse personal datum negative impact company business reputation company subject privacy datum protection law globe impose broad compliance obligation collection use storage access transfer protection personal datum breach requirement result substantial fine penalty private right action claim damage reputation business new privacy law expect territory great privacy enforcement governmental authority globally particularly datum localization requirement international datum flow company establish privacy compliance program control business worldwide require comply technology datadriven initiative prioritize company involve multiple vendor party potential risk control impose cross border datum flow unauthorized access loss personal datum internal external threat impact business operation research activity item unresolved staff comment applicable item property company subsidiary operate manufacturing facility occupy approximately million square foot floor space manufacturing facility industry segment company business approximately follow square foot segment thousand consumer health pharmaceutical medical device worldwide total facility consumer health segment pharmaceutical segment medical device segment outside facility consumer health segment pharmaceutical segment medical device segment location manufacture facility major geographic area world follow number square feet geographic area facility thousands united states europe western hemisphere exclude africa asia pacific worldwide total addition manufacture facility discuss company maintain numerous office warehouse facility world company subsidiary generally seek lease manufacturing facility principally nonus location lease office warehouse facility lease company engage contract manufacturer company commit maintain property good operating condition mcneilppc inc johnson johnson consumer inc mcneilppc operate consent decree sign fda govern certain mcneil consumer healthcare manufacturing operation require mcneilppc remediate facility operate lancaster pennsylvania fort washington pennsylvania las piedras puerto rico consent decree follow fda inspection mcneilppc receive notification fda manufacture facility conformity applicable law regulation commercial production restart consent decree receiving notice fda compliance applicable law regulation facility subject fiveyear audit period thirdparty cgmp expert thirdparty expert continue reassess site time fda inspection facility delay covid complete consent decree vacate july segment information addition property plant equipment contain note segment business geographic area note consolidated financial statement include item report item legal proceeding information call item incorporate reference information set forth note legal proceeding note consolidated financial statement include item report item safety disclosure applicable executive officer registrant list executive officer company family relationship executive officer arrangement understand executive officer person pursuant executive officer select annual meeting board director executive officer elect board hold office year respective successor elect qualified early resignation removal information regard director company incorporate reference material caption item election director proxy statement age position vanessa broadhurst member executive committee executive vice president global corporate affairs joaquin duato chief executive officer chairman executive committee peter fasolo phd member executive committee executive vice president chief human resource officer william hait member executive committee executive vice president chief external innovation medical safety global public health officer mathai mamman member executive committee executive vice president pharmaceuticals ashley mcevoy member executive committee executive vice president worldwide chairman medical devices thibaut mongon member executive committee executive vice president worldwide chairman consumer health james swanson member executive committee executive vice president chief information officer jennifer taubert member executive committee executive vice president worldwide chairman pharmaceutical michael ullmann member executive committee executive vice president general counsel kathryn wengel member executive committee executive vice president chief global supply chain officer joseph wolk member executive committee executive vice president chief financial officer broadhurst join company worldwide vice president anemia oncology supportive care go vice president cardiovascular institutional franchise president janssen therapeutics president internal medicine hold general manager role amgen inflammation cardiovascular cardiovascular bone broadhurst rejoin johnson johnson president cardiovascular metabolism member janssen americas leadership team role provide operational oversight portfolio janssen medicines puerto rico canada appoint company group chairman global commercial strategy organization broadhurst name executive vice president global corporate affair member executive committee lead company global marketing communication design philanthropy function duato chief executive officer chairman executive committee join board director january join company janssenfarmaceutica spain subsidiary company hold executive position increase responsibility business sector multiple geography function name company group chairman pharmaceutical name worldwide chairman pharmaceutical duato member executive committee name executive vice president worldwide chairman pharmaceuticals july duato promote vice chairman executive committee provide strategic direction pharmaceutical consumer health sector oversee global supply chain information technology health wellness team dual citizen spain united states duato international perspective global lens give deep appreciation diverse thought opinion fasolo join company worldwide vice president human resource medical device segment subsequently serve company chief talent officer leave johnson johnson join kohlberg kravis roberts chief talent officer fasolo return company vice president global human resource member executive committee april name executive vice president chief human resource officer fasolo responsibility global talent recruiting diversity compensation benefit employee relation aspect human resource agenda company serve board human resource policy association tufts university save child name fellow national academy human resources hait join company senior vice president worldwide head oncology research serve global therapeutic area head oncology global head janssen research development global head johnson johnson global external innovation executive vice president chief external innovation medical safety global public health officer member executive committee responsible lead external source creation transformational innovation help johnson johnson achieve mission improve human health utilize company excellence pharmaceutical medical device consumer product oversight global public health office chief medical officer mamman join company global head janssen pharmaceutical companies johnson johnson prior join janssen june mammen senior vice president merck research laboratory responsible research area cardiovascular metabolic renal disease oncologylmmunooncology immunology prior merck lead theravance company cofounde san francisco bay area base work harvard university name executive vice president pharmaceutical member executive committee responsible team mission transformational medicine unequivocal benefit patient worldwide work wide range therapeutic area biological pathway area oncology cardiovascular metabolic disease retinal disease pulmonary hypertension immunology neuroscience infectious disease vaccine therapeutic area fuel worldclass global function discovery science manufacture regulatory affair development operation datum science mcevoy join company assistant brand manager mcneil consumer health subsidiary company advance position increase responsibility appoint company group chairman vision care follow company group chairman consumer medical device july mcevoy promote executive vice president worldwide chairman medical device member executive committee mcevoy responsibility surgery orthopaedic interventional solution eye health business ethicon depuy synthe biosense webster johnson johnson vision mongon join company director marketing vision care group france subsequently hold position increase responsibility transition pharmaceutical sector global commercial strategy leader neuroscience therapeutic area join consumer health sector company group chairman asiapacific promote executive vice president worldwide chairman consumer health member executive committee mongon responsibility global development johnson johnsons health wellness product solution beauty otc oral care baby care womens health wound care swanson rejoin company chief information officer johnson johnson bayer crop science serve member executive leadership team cio head digitaltransformation swanson hold position increase responsibility company include project manager director director vice president chief information officer swanson responsible enhance johnson johnsons business impact shape direction strategic use technology swanson executive vice president chief information officer join executive committee effective january taubert join company worldwide vice president hold executive position increase responsibility pharmaceutical sector appoint company group chairman north america pharmaceutical company group chairman americas pharmaceuticals july taubert promote executive vice president worldwide chairman pharmaceutical member executive committee taubert responsible pharmaceutical sector globally include shape company strategy transformational medical innovation successfully bring market critical new medicine significantly improve live patient live cancer immunerelate disease cardiovascular disease infectious disease pulmonary hypertension mental illness ullmann join company corporate attorney law department appoint corporate secretary serve role time hold management position law department name general counsel medical device diagnostic appoint vice president general counsel member executive committee april ullmann name executive vice president general counsel ullmann worldwide responsibility legal government affair policy global security aviation healthcare compliance global brand protection privacy wengel join company project engineer engineering supervisor janssen subsidiary company tenure company hold variety strategic leadership executive position global enterprise role operation quality engineer new product information technology technical business function wengel chief quality officer company promote vice president johnson johnson supply chain july promote executive vice president chief global supply chain officer member executive committee wengel enterprisewide responsibility supply chain quality compliance procurement engineering property service environmental health safety sustainability wolk join company finance manager business development orthomcneil subsidiary company year hold variety senior leadership role segment function company subsidiary pharmaceutical medical device supply chain serve vice president finance chief financial officer janssen pharmaceutical companies johnson johnson wolk vice president investor relation july appoint executive vice president chief financial officer member executive committee wolk play strategic role overall management company lead development execution company global longterm financial strategy item market registrant common equity relate stockholder matter issuer purchase equity security february record holder common stock company additional information call item incorporate reference follow section report note common stock stock option plan stock compensation agreement note consolidated financial statement include item item security ownership certain beneficial owner management relate stockholder matter equity compensation plan information issuer purchase equity security follow table provide information respect common stock purchase company fiscal fourth quarter common stock purchase open market systematic plan meet need company compensation program repurchase include stockforstock option exercise settle fiscal fourth quarter total number maximum number share unit approximate dollar purchase value share total number publicly unit share avg price announce plan purchase fiscal period purchase pay share program plan programs october october november november november january total fiscal fourth quarter company repurchase aggregate share johnson johnson common stock openmarket transaction purchase openmarket transaction systematic plan meet need company compensation program item reserve item management discussion analysis result operation financial condition organization business segment description company business segment johnson johnson subsidiaries company approximately employee worldwide engage research development manufacture sale broad range product healthcare field company conduct business virtually country world primary focus product relate human health wellbee company organize business segment consumer health pharmaceutical medical device consumer health segment include broad range product baby care oral care skin healthbeauty overthe counter pharmaceutical womens health wound care market product market general public sell online ecommerce retail outlet distributor world pharmaceutical segment focus therapeutic area include immunology infectious disease neuroscience oncology pulmonary hypertension cardiovascular metabolic disease product segment distribute directly retailer wholesaler distributor hospitals healthcare professional prescription use medical device segment include broad range product orthopaedic surgery interventional solution cardiovascular neurovascular vision field product distribute wholesaler hospital retailer principally professional field physician nurse hospitals eye care professional clinic executive committee johnson johnson principal management group responsible strategic operation allocation resource company committee oversee coordinate activitie consumer health pharmaceutical medical device business segment product line company compete company locally globally world competition exist product line regard number size compete company involve competition research involve development improvement new exist product process particularly significant development new innovative product protect underlie intellectual property company product portfolio important company success area business competitive environment require substantial investment continue research addition development maintenance customer demand company consumer product involve significant expenditure advertising promotion management objectives credo foundation company purpose blend heart science ingenuity profoundly change trajectory health humanity company commit bring breadth depth ensure health people today future generation unite common ambition company poise fulfill purpose successfully meet demand rapidly evolve market compete company broadly base human healthcare commit create value develop accessible high quality innovative product service new product introduce past year account approximately sale billion invest research development reflect management commitment create lifeenhancing innovation create value partnership profoundly change trajectory health humanity critical driver company success diversity employee worldwide employee empower inspire lead company credo purpose guide allow employee use company reach size advance company purpose lead agility urgency leverage extensive resource enterprise enable company innovate execute excellence ensure company remain focused address unmet need society day invest endure impact ultimately deliver value patient consumer healthcare professional employee communitie shareholdersresult operation analysis consolidate sale discussion result operation financial condition pertain fiscal year company annual report fiscal year end january item management discussion analysis result operation financial condition worldwide sale increase billion compare increase sale change consist follow sale increasedecrease volume price currency total net impact acquisition divestiture worldwide sale growth negative impact negative impact sale company billion billion represent increase sale international company billion billion represent increase decrease fiveyear compound annual growth rate worldwide international sale respectively tenyear compound annual growth rate worldwide international sale respectively sale company europe achieve growth compare prior year include operational growth positive currency impact sale company western hemisphere exclude achieve growth compare prior year include operational growth positive currency impact sale company asiapacific africa region achieve growth compare prior year include operational growth positive currency impact company estimate inclusion week fiscal year result negatively impact comparative sale growth approximately note consolidated financial statement annual closing date detail additional week add day sale add week worth operating cost net earning impact negligible company utilize wholesaler distribute product segment represent approximately total consolidated revenue company wholesaler distribute product segment represent approximately total consolidated revenuesnote value rounded analysis sale business segment consumer health segment consumer health segment sale billion increase include operational growth positive currency impact consumer health segment sale billion increase international sale billion increase include operational growth positive currency impact acquisition divestiture net negative impact operational sale growth worldwide consumer health segment major consumer health franchise sale change dollar million otc skin healthbeauty oral care baby care womens health wound careother total consumer health sale otc franchise sale billion increase compare prior year growth primarily attributable analgesic tylenol motrin digestive health hydration benefit offer orsl skin healthbeauty franchise sale billion increase compare prior year growth primarily covid recovery strong performance neutrogena aveeno ecommerce acceleration partially offset divestiture cilabo sedona business asia pacific external supply constraint oral care franchise sale billion increase compare prior year market growth strong performance asia pacific region successful brand build promotional campaign positive impact currency offset negative impact floss divestiture external supply constraint baby care franchise sale billion increase compare prior year growth drive aveeno asia pacific ecommerce strength innovation covid recovery women health franchise sale billion increase compare prior year primarily drive covid market recovery favorable price strong brand building asia pacific partially offset disruption europe flooding wound careother franchise sale billion increase compare prior year growth strong performance bandaid brand adhesive bandage partially offset product discontinuation competitive pressure asia pacific november company announce intention separate company consumer health business intention create new publicly trade company company target completion plan separation month initial announcement pharmaceutical segment pharmaceutical segment sale billion increase include operational growth positive currency impact sale billion increase international sale billion increase include operational growth positive currency impact acquisition divestiture net negative impact operational sale growth worldwide pharmaceutical segment adjustment previous sale reserve estimate approximately billion billion fiscal year respectively major pharmaceutical therapeutic area sale change dollar million total immunology remicade simponi simponi aria stelara tremfya immunology total infectious disease covid vaccine edurant rilpivirine prezista prezcobix rezolsta symtuza infectious disease total neuroscience concerta methylphenidate invega sustenna xeplion invega trinza trevicta risperdal consta neuroscience total oncology darzalex erleada imbruvica zytiga abiraterone acetate oncology total pulmonary hypertension opsumit uptravi pulmonary hypertension total cardiovascular metabolism xarelto invokana invokamet procrit eprex total pharmaceutical sale certain prior year amount reclassify conform current year presentation percentage great meaningful inclusive velcade previously disclose separately immunology product achieve sale billion represent increase compare prior year drive strong uptake stelara ustekinumab crohn disease ulcerative colitis strength tremfya guselkumab psoriasis uptake psoriatic arthritis partially offset low sale remicade infliximab biosimilar competition biosimilar version remicade introduce united states certain market outside united states additional competitor continue enter market continue infliximab biosimilar competition result reduction sale remicade late expiring united states patent stelara ustekinumab expire september stelara ustekinumab sale fiscal approximately billion expiration product patent loss market exclusivity likely result reduction sale infectious disease product achieve sale billion represent increase compare prior year growth primarily drive contribution covid vaccine partially offset low sale prezista prezcobix rezolsta darunavircobicistat increase competition loss exclusivity prezista certain country outside neuroscience product achieve sale billion represent increase compare prior year paliperidone longacte injectable growth drive sale invega sustenna xeplion paliperidone palmitate invega trinza trevicta new patient start persistence launch invega hafyera oncology product achieve sale billion represent increase compare prior year contributor growth strong sale darzalex daratumumab drive continue strong market growth share gain region solid uptake subcutaneous formulation launch continued global launch uptake erleada apalutamide imbruvica ibrutinib growth primarily drive market continue share leadership growth imbruvica ibrutinib partially offset competitive pressure novel oral agent covid related market dynamic include delay new patient start pulmonary hypertension product achieve sale billion represent increase compare prior year sale growth opsumit macitentan uptravi selexipag continued share gain market growth cardiovascularmetabolismother product sale billion decline compare prior year decline primarily attributable low sale invokana invokamet canagliflozin share erosion procrit eprex epoetin alfa biosimilar competition company advanced pipeline regulatory submission approval new drug additional indication exist drug follow product chemical indication approval approval filing filing byannli maintenance treatment schizophrenia adult cabenuva rilpivirine hiv treatment use month cabotegravir covid vaccine covid emergency use covid vaccine covid emergency use booster shoot darzalex subcutaneous formulation treatment newly daratumumab diagnose systemic light chain amyloidosis gain additional approval pretreate multiple myeloma darzalex faspro combination carfilzomib dexamethasone daratumumab patient multiple myeloma subsequent hyaluronidasefihj relapse invega hafyera twiceyearly treatment adult paliperidone palmitate schizophrenia ponvory ponesimod treatment adult relapse form multiple sclerosis active disease define clinical imaging feature ponvory ponesimod oral treatment adult relapse multiple sclerosis rybrevant treatment patient nonsmall cell lung cancer amivantamabvmjw egfr exon insertion mutation spravato rapid reduction depressive symptom psychiatric esketamine emergency patient major depressive disorder stelara treatment pediatric patient juvenille psoriatic ustekinumab arthritis teclistamab treatment patient relapse refractory multiple myeloma uptravi intravenous use adult patient pulmonary arterial selexipag hypertension pah xarelto help prevent treat blood clot pediatric patient rivaroxaban xarelto expand peripheral artery disease pad indication rivaroxaban include patient lowerextremity revascularization ler medical device segment medical device segment sale billion increase include operational growth positive currency impact sale billion increase compare prior year international sale billion increase compare prior year include operational growth positive currency impact net impact acquisition divestiture medical device segment worldwide operational sale growth negative primarily divestiture advanced sterilization product asp company see market recovery global procedural volume medical device segment compare prior year significant negative impact covid procedural volume recovery primary driver sale earning growth compare prior year major medical device franchise sale change dollar million surgery advanced general orthopaedic hip knee trauma spine sport vision contact lensesother surgical interventional solution total medical device sale surgery franchise achieve sale billion represent increase growth advanced surgery primarily drive endocutter biosurgery energy product attributable market recovery market expansion success new product offset competitive pressure growth general surgery primarily drive market recovery continue strength suture portfolio partially offset impact asp divestiture prior year orthopaedic franchise achieve sale billion represent increase growth hip reflect market recovery combine continued strength portfolio include actis stem enable technology kincise vely hip navigation growth knee primarily drive procedure recovery new product introduction growth trauma drive global market recovery uptake new product growth spine sport primarily drive procedure recovery new product introduction vision franchise achieve sale billion represent increase contact lensesother operational growth market recovery market share gain new product surgical vision operational growth primarily market recovery uptake recently launch product interventional solution franchise achieve sale billion increase growth electrophysiology stroke business drive market recovery success new product commercial strategy begin fiscal quarter medical device segment refer medtech segment analysis consolidate earning provision taxis income consolidated earning provision taxis income billion billion year respectively percent sale consolidated earning provision taxis income respectively dollar billion percentage chart percent total sale cost product sell sell marketing administrative expense dollar billion percentage chart percent total sale cost product sell decrease percent sale drive nonrecurre prior year covid production relate slowdown relate inventory impact fix cost deleverage medical device business fiscal favorable mix pharmaceutical business enterprise level high percentage sale come pharmaceutical business supply chain efficiency consumer health segment intangible asset amortization expense include cost product sell billion fiscal year sell marketing administrative expense decrease percent sale drive leverage medical device business result recovery sale prior year impact covid partially offset increase brand marketing expense consumer health business research development expense research development expense segment business follow dollar million sale sale consumer health pharmaceutical medical device total research development expense percent increasedecrease prior year percent segment sale research development activity represent significant company business expenditure relate process discover testing develop new product upfront payment developmental milestone improve exist product ensure product efficacy regulatory compliance prior launch company remain committed invest research development aim deliver high quality innovative product research development increase percent sale primarily drive general portfolio progression pharmaceutical business covid vaccine expense net governmental reimbursement inprocess research development iprd fiscal year company record partial iprd charge billion primarily relate expect development delay general surgery digital robotic platform ottava acquire auris health acquisition impairment charge calculate base revision discount cash flow valuation model reflect delay human procedure approximately year initial acquisition model assumption second half company continue monitor remain billion ottava platform intangible asset development program activity ongoing fiscal year company record iprd charge billion primarily relate partial impairment time progression digital surgery platform acquire auris health acquisition january subsequent fiscal year additional information efficacy available lead company decision terminate development bermekimab atopic dermatitis company record intangible asset impairment charge approximately billion related inprocess research development asset bermekimab jnj investigational drug treatment hidradenitis suppurativa impairment charge relate indication nonrecognize subsequent event reflect quarter financial statement company acquire right bermekimab xbiotech inc fiscal year income expense net income expense net account company record gain loss relate sale writedown certain investment equity security hold johnson johnson innovation jjdc inc jjdc unrealized gain loss investment income loss associate certain employee benefit program gain loss divestiture certain transactional currency gain loss acquisitionrelate cost litigation accrual settlement royalty income income expense net fiscal year favorable billion compare prior year primarily follow dollar billionsincomeexpense change litigation expense acquisition integration divestiture relate gainslosse security restructuring relate employee benefit plan relate total income expense net primarily related talc risperdal primarily related talc opioid litigation settlement rimarily relate divestiture gain pharmaceutical brand outside primarily drive contingent consideration reversal approximately billion related timing certain developmental milestone associate auris health acquisition include consumer health separation cost billion cost future year expect significantly high interest income expense fiscal year include net interest expense million compare million net interest expense fiscal year primarily low rate interest earn cash balance high average debt balance partially offset benefit net investment hedge cash cash equivalent marketable security total billion end average billion compare cash cash equivalent marketable security total billion billion average cash balance total debt balance end billion average debt balance billion compare billion end average debt balance billion income tax segment income loss tax segment business follow income tax segment sale percent segment sale dollar million consumer health pharmaceutical medical device total net expense allocate segment earning provision taxis income note consolidated financial statement detail amount allocate segment include interest income expense general corporate income expense consumer health segment consumer health segment income tax percent sale versus loss tax increase income tax percent sale primarily drive follow litigation expense include billion talc expense include billion talc expense supply chain efficiency partially offset increase brand marketing expense commodity inflation pharmaceutical segment pharmaceutical segment income tax percent sale versus increase income tax percent sale primarily drive follow divestiture gain billion related pharmaceutical brand outside fiscal litigation expense include billion primarily relate risperdal include billion primarily related opioid litigation settlement partially offset research development investment covid vaccine net governmental reimbursement generalportfolio progression medical device segment medical device segment income tax percent sale versus increase income tax percent sale primarily drive follow recovery prior year covid production relate slow down relate inventory impact overall expense leverage result medical device sale recovery litigation expense billion billion partially offset contingent consideration reversal approximately billion fiscal relate timing certain developmental milestone associate auris health acquisition high iprd charge billion billion related general surgery offer digital robotic ottava acquire auris health acquisition restructure fiscal second quarter company announce plan implement action global supply chain intend enable company focus resource increase investment critical capability technology solution necessary manufacture supply product portfolio future enhance agility drive growth company expect supply chain action include expand use strategic collaboration bolster initiative reduce complexity improve costcompetitiveness enhancing capability optimize network discussion specific future action ongoing subject relevant consultation requirement finalize total company expect action generate approximately billion annual pretax cost saving substantially deliver end company expect record pretax restructuring charge approximately billion company estimate approximately cumulative pretax cost result cash outlay company record pretax charge billion include follow line consolidate statement earning billion restructuring billion income expense billion cost product sell total project cost approximately billion record restructure announce program set complete end note consolidated financial statement additional detail relate restructuring program provision taxis income worldwide effective income tax rate discussion relate fiscal provision taxis refer note consolidated financial statement liquidity capital resource liquidity cash flow cash cash equivalent billion end compare billion end primary source use cash contribute billion increase dollar billion cash cash equivalent balance cash generate operating activity net cash investing activity net cash financing activity effect exchange rate round cash cash equivalent balance addition company billion marketable security end fiscal year billion end fiscal year note consolidated financial statement additional detail cash cash equivalent marketable securitiescash flow operation billion result dollar billion net earning noncash expense adjustment primarily depreciation amortization stockbase compensation asset writedown partially offset defer tax provision net gain sale assetsbusinesse credit loss account receivable allowance decrease current noncurrent liability increase account payable accrue liability increase account receivable inventory current noncurrent asset cash flow operation investing activity use billion cash primarily dollar billion addition property plant equipment net purchase investment proceed disposal assetsbusinesse net credit support agreement activity net acquisition primarily license milestone round net cash investing activity financing activity use billion cash primarily dollar billion dividend shareholder repurchase common stock employee share program net repayment short long term debt proceed stock option exercisedemployee withholding tax stock award net credit support agreement activity net round net cash financing activity january company note payable longterm debt excess cash cash equivalent marketable security january net debt position billion compare prior year billion decrease net debt position repayment debt increase cash cash equivalent marketable security generating operation debt balance end billion compare billion consider recent market condition ongoing covid crisis company evaluate operate cash flow liquidity profile foresee significant incremental risk company anticipate operate cash flow ability raise fund external source borrowing capacity exist committed credit facility access commercial paper market continue provide sufficient resource fund operating need include company approximate billion contractual supply commitment associate development covid vaccine opioid litigation settlement billion establishment billion trust talc relate liability note consolidated financial statement additional detail addition company monitor global capital market ongoing basis time time raise capital market condition favorable effective begin fiscal tax cut job act currently require company deduct international research development expenditure tax purpose year instead current fiscal year result company expect increase annual cash tax payment treasury incremental billion begin fiscal company concurrently record defer tax benefit future amortization research development tax purpose company expect significant impact effective tax rate relate change requirement expense incur unchanged gaap purpose impact pretax expense affect provision additionally result tax cut job act tcja company access cash outside significantly reduce cost fiscal quarter accordance term agreement associate acquisition actelion company undrawn credit facility idorsia terminate follow table summarize company material contractual obligation aggregate maturity january satisfy obligation company intend use cash operation tax legislation interest dollar millions tcja debt obligation debt obligation total total tax matter note consolidated financial statement table include activity relate business combination company approximate billion contractual supply commitment associate development covid vaccine finance market risk company use financial instrument manage impact foreign exchange rate change cash flow accordingly company enter forward foreign exchange contract protect value certain foreign currency asset liability hedge future foreign currency transaction primarily relate product cost gain loss contract offset gain loss underlie transaction appreciation dollar january market rate increase unrealized value company forward contract billion conversely depreciation dollar january market rate decrease unrealized value company forward contract billion scenario gain loss forward contract offset gain loss underlie transaction impact future anticipate earning cash flow company hedge exposure fluctuation currency exchange rate effect certain asset liability foreign currency enter currency swap contract change spread foreign interest rate companys interest rate sensitive financial instrument increase decrease unrealized value company swap contract approximately billion scenario maturity gain loss swap contract offset gain loss underlie transaction impact future anticipate cash flow company enter financial instrument trade speculative purpose company policy enter contract party investment grade credit rating counterpartie contract major financial institution significant concentration exposure counterparty management believe risk loss remote company enter credit support agreement csa certain derivative counterpartie establish collateral threshold base respective credit rating netting agreement note consolidated financial statement additional detail credit support agreement company invest fix rate float rate interest earn security carry degree interest rate risk fair market value fix rate security adversely impact rise interest rate float rate security produce income predict interest rate fall basis point change spread company interest rate sensitive investment increase decrease unrealized value cash equivalent current marketable security approximately billion company access substantial source fund numerous bank worldwide september company secure new day credit facility total credit available company approximate billion expire september interest charge borrowing credit line agreement base secure overnight financing rate sofr reference rate applicable market rate allow plus applicable margin commitment fee agreement material total borrowing end billion billion respectively decrease borrowing repayment debt net debt cash current marketable security net debt billion compare net debt billion total debt represent total capital shareholder equity total debt total capital shareholder equity share end compare yearend summary borrowing find note consolidated financial statement dividend company increase dividend consecutive year cash dividend pay share share january board director declare regular cash dividend share payable march shareholders record february information critical accounting policy estimate management discussion analysis result operation financial condition base company consolidate financial statement prepare accordance accounting principle generally accept gaap preparation financial statement require management estimate assumption affect amount report revenue expense asset liability relate disclosure actual result differ estimate company believe understand certain key accounting policy estimate essential achieve insight company operating result financial condition key accounting policy include revenue recognition income taxis legal selfinsurance contingency valuation longlive asset assumption determine amount record pension employee benefit plan account stock base award extent covid impact company business financial result depend numerous evolve factor include limited magnitude duration covid extent impact worldwide macroeconomic condition include interest rate employment rate health insurance coverage speed anticipate recovery governmental business reaction pandemic company assess certain accounting matter generally require consideration forecast financial information context information reasonably available company unknown future impact covid january date report accounting matter assess include limited company allowance doubtful account credit loss inventory relate reserve accrue rebate associate reserve carry value goodwill longlive asset material impact company consolidate financial statement year end january company future assessment magnitude duration covid factor result material impact company consolidate financial statement future reporting period revenue recognition company recognize revenue product sale obligation term contract customer satisfy generally occur transfer control good customer company global payment term typically day provision certain rebate sale incentive trade promotion coupon product return discount customer governmental clawback provision account variable consideration record reduction sale product discount grant base term arrangement direct indirect market participant market condition include consideration competitor pricing rebate estimate base contractual term historical experience patient outcome trend analysis project market condition market serve company evaluate market condition product group product primarily analysis wholesaler thirdparty sellthrough market research datum internally generate information sale return estimate record base historical sale return information product exhibit unusual sale return pattern date competition marketing matter specifically investigate analyze accounting sale return accrual sale return allowance represent reserve product return expiration destruction field specific area product recall sale return reserve base historical return trend product market percent gross sale accordance company accounting policy company generally issue credit customer return good company sale return reserve account accordance gaap guidance revenue recognition right return exist sale return reserve record sale value sale return consumer health pharmaceutical segment exclusively resalable sale return certain franchise medical device segment typically resalable material company infrequently exchange product inventory return product sale return reserve total company approximately annual net trade sale fiscal year promotional program product list allowance cooperative advertising arrangement record period relate sale continue promotional program include coupon volumebase sale incentive program redemption cost consumer coupon base historical redemption experience product value volumebase incentive program base estimate sale volume incentive period record product soldthese arrangement evaluate determine appropriate amount defer record reduction revenue company earn profitshare payment collaborative arrangement certain product include sale customer year present profitshare payment total revenue include sale customer addition company enter collaboration arrangement contain multiple revenue generating activity amount collaborative partner arrangement recognize activity perform deliver base relative selling price upfront fee receive arrangement defer recognize performance period note consolidated financial statement additional disclosure collaboration reasonably likely change assumption calculate accrual rebate return promotion anticipate material effect financial statement company currently disclose impact change assumption quarterly annual filing material financial statement impact table progression accrue rebate return promotion reserve doubtful account reserve cash discount segment business fiscal year end january january consumer health segment balance begin balance dollar million period accrual paymentscredit end period accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total include reserve customer rebate million january million january record contra asset pharmaceutical segment balance begin paymentscredit balance dollar million period accrual end period accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total include reserve customer rebate million january million january record contra asset include prior period adjustment medical device segment balance begin balance dollar million period accrual paymentscredit end period accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total include reserve customer rebate million january million january record contra asset income taxis income taxis record base amount refundable payable current year include result difference gaap accounting tax reporting record defer tax asset liability company estimate defer tax asset liability base enact tax regulation rate future change tax law rate affect record defer tax asset liability company unrecognize tax benefit uncertain tax position company follow gaap prescribe recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return management believe change estimate material effect company result operation cash flow financial position company record defer tax liability undistribute earning prior december international subsidiary company provide defer taxis undistribute earning subsequent january certain international subsidiary earning consider indefinitely reinveste company intend continue reinvest earning international operation company decide later date repatriate earning company require provide net tax effect amount company estimate tax effect repatriation approximately billion currently enact tax law regulation current currency exchange rate include possible benefit foreign tax credit substantially offset cost note note consolidated financial statement information income taxis legal self insurance contingency company record accrual contingency include legal proceeding product liability claim arise normal course business accrual base management judgment probability loss applicable actuarially determined estimate company self insurance whollyowne captive insurance company addition accrual self insurance program claim exceed insurance coverage accrue loss probable amount reasonably estimate company follow provision gaap recording litigation relate contingency liability record loss probable reasonably estimate note consolidated financial statement information product liability legal proceeding longlive intangible asset company assess change qualitatively quantitatively economic condition make assumption estimate future cash flow evaluate value company property plant equipment goodwill intangible asset assumption estimate change time necessary company record impairment charge employee benefit plan company sponsor retirement pension plan include define benefit define contribution termination indemnity plan cover employee worldwide plan base assumption discount rate expect return plan asset mortality rate expect salary increase healthcare cost trend rate attrition rate note consolidated financial statement detail rate stock base compensation company recognize compensation expense associate issuance equity instrument employee service base type equity instrument fair value estimate date grant blackschole option valuation model combination blackschole option valuation model monte carlo valuation model expense financial statement service period input assumption determine fair value expect life expect volatility riskfree rate expect dividend yield prior fiscal performance share unit fair market value calculate component goal date grant operational sale adjust operational earning share relative total shareholder return begin fiscal performance share unit fair market value calculate component goal date grant adjust operational earning share relative total shareholder return fair value earning share goal performance share unit estimate date grant fair market value share time award discount dividend pay performance share unit vest period fair value relative total shareholder return goal performance share unit estimate date grant monte carlo valuation model note consolidated financial statement additional information new accounting pronouncement refer note consolidated financial statement recently adopt accounting pronouncement recently issue accounting pronouncement adopt january economic market factor covid consideration business continuity company consider internal external factor assess potential impact covid business financial result base information available time follow operating model company diversify business model healthcare industry flexibility design manufacturing research development clinical operation commercial capability supply chain company continue leverage global manufacturing footprint dualsource capability closely monitor maintain critical inventory major distribution center away highrisk area help ensure adequate effective distribution business continuity robust active business continuity plan company network instrumental prepare company event like covid ability meet majority patient consumer need remain uninterrupted workforce company procedure place protect essential workforce manufacturing distribution commercial research operation ensure appropriate remote working protocol establish employee liquidity company highquality credit rating allow company superior access financial capital market foreseeable future domestic foreign legislation company continue assess evaluate ongoing global legislative effort combat covid impact economy sector participate currently recent legislative act place expect material impact company operation fiscal company enter series contract manufacturing arrangement vaccine production party contract manufacturing organization arrangement provide company future supplemental commercial capacity vaccine production potentially transferable right production capacity require amount pay service deliver contractually obligate pay contract manufacturing organization approximately billion reflect prepay expense asset accrue liability liability account company consolidated balance sheet execution agreement additionally company enter certain vaccine development cost sharing arrangement government relate organization company continue evaluate monitor internal external supply arrangement include contract emergent biosolution relate production activity bayview maryland facility company establish global vaccine supply network addition internal manufacturing site leiden netherlands manufacture site involve production vaccine different country continent company believe disruption vaccine manufacturing site result delay material financial impact company consolidate financial statement result company aware product environment decade policymaker consumer business express concern rise cost healthcare response concern company longstande policy pricing product responsibly period weight average compound annual growth rate company net price increase healthcare product prescription overthe counter drugs hospital professional product consumer price index cpi company operate certain country economic condition continue present significant challenge company continue monitor situation appropriate action inflation rate continue effect worldwide economy consequently way company operate company account operation argentina venezuela highly inflationary prior threeyear cumulative inflation rate surpass material impact company result period face increase cost company strive maintain profit margin cost reduction program productivity improvement periodic price increase company expose fluctuation currency exchange rate change value dollar compare foreign currency company sale income expense increase decrease translation foreign sale approximately billion net income approximately billion government world consider proposal change tax law include increase decrease exist statutory tax rate connection government initiative company require disclose information tax authority operation world lead great audit scrutiny profit earn country change statutory tax rate country result revaluation company defer tax asset liability relate particular jurisdiction period new tax law enact change result expense benefit record company consolidate statement earning company closely monitor proposal arise country operate change statutory tax rate occur time related expense benefit record material fiscal quarter year law change enact company face worldwide healthcare change continue result pricing pressure includehealthcare cost containment government legislation relate sale promotion reimbursement healthcare product change behavior spend pattern purchaser healthcare product service include delay medical procedure ration prescription medication reduce frequency physician visit forego healthcare insurance coverage result current global economic downturn continue impact company business company operate environment increasingly hostile intellectual property right firm file abbreviate new drug application biosimilar biological product application fda challenge coverage andor validity company patent seek market generic biosimilar form company key pharmaceutical product prior expiration applicable patent cover product event company successful defend patent claim challenge result lawsuit generic biosimilar version product issue introduce market result potential substantial market share revenue loss product result noncash impairment charge associate intangible asset risk competitor launch generic biosimilar version product issue follow regulatory approval valid patent place legal proceeding johnson johnson certain subsidiary involve lawsuit claim product liability intellectual property commercial employment indemnification matter governmental investigation legal proceeding arise time time ordinary course business company record accrual loss contingency associate legal matter probable liability incur loss reasonably estimate january company determine liability associate certain litigation matter probable reasonably estimate company accrue matter continue monitor related legal issue adjust accrual warrant base new information development accordance asc litigation regulatory matter discuss loss probable reasonably possible company unable estimate possible loss range loss amount accrue amount accrue legal contingency result complex series judgment future event uncertainty rely heavily estimate assumption include time relate payment ability estimate judgment affect factor include thing damage seek proceeding unsubstantiated indeterminate scientific legal discovery commence complete proceeding early stage matter present legal uncertainty significant fact dispute procedural jurisdictional issue uncertainty unpredictability number potential claim ability achieve comprehensive multiparty settlement complexity relate crossclaim counterclaim andor numerous party involve extent adverse award judgment verdict render company company record accrual loss determine probable reasonably estimate company opinion base examination matter experience date discussion counsel ultimate outcome legal proceeding net liability accrue company balance sheet expect material adverse effect company financial position resolution increase accrual matter report period material adverse effect company result operation cash flow period note consolidated financial statement include item report information legal proceeding common stock company common stock list new york stock exchange symbol jnj february record holders common stock company item quantitative qualitative disclosure market risk information call item incorporate reference item management discussion analysis result operation financial condition liquidity capital resource finance market risk report note summary significant accounting policy financial instrument note consolidated financial statement include item report item financial statement supplementary datum index audit consolidated financial statement consolidate balance sheet consolidate statement earning consolidate statement comprehensive income consolidate statement equity consolidate statement cash flow note consolidated financial statement report independent register public accounting firm pcaob management report internal control financial reporting johnson johnson subsidiaries consolidate balance sheet january january dollar million share share amount note asset current asset cash cash equivalent note marketable security note account receivable trade allowance doubtful account inventory note prepay expense receivables total current asset property plant equipment net note intangible asset net note goodwill note defer taxis income note asset total asset liability shareholder equity current liability loan note payable note account payable accrue liability accrue rebate return promotions accrue compensation employee relate obligation accrue taxis income note total current liability longterm debt note defer taxis income note employee relate obligation note longterm taxis payable note liability total liability commitment contingency note shareholder equity prefer stock par value authorize unissued share common stock par value share note authorize share issue share accumulate comprehensive income loss note retain earning common stock hold treasury cost note share share total shareholder equity total liability shareholder equity note consolidated financial statement johnson johnson subsidiaries consolidate statement earning dollar share million share amount note sale customer cost product sell gross profit selling marketing administrative expense research development expense inprocess research development note interest income interest expense net portion capitalize note income expense net restructure note earning provision taxis income provision taxis income note net earning net earning share note basic diluted average share outstanding note basic diluted note consolidated financial statement johnson johnson subsidiaries consolidate statement comprehensive income dollar million note net earning comprehensive income loss net tax foreign currency translation security unrealize hold gain loss arise period reclassification earning net change employee benefit plan prior service credit cost net amortization gain loss net amortization effect exchange rate net change derivative hedge unrealize gain loss arise period reclassification earning net change comprehensive income loss comprehensive income tax effect comprehensive income fiscal year respectively foreign currency translation million million million security million employee benefit plan million million million derivative hedge million million million note consolidated financial statement johnson johnson subsidiaries consolidate statement equity dollar million note accumulate common stock treasury retain comprehensive issue stock total earning income loss balance december net earning cash dividend pay share employee compensation stock option plan repurchase common stock comprehensive income loss net tax balance december net earning cash dividend pay share employee compensation stock option plan repurchase common stock comprehensive income loss net tax balance january net earning cash dividend pay share employee compensation stock option plan repurchase common stock comprehensive income loss net tax balance january note consolidated financial statement johnson johnson subsidiaries consolidate statement cash flow dollar million note cash flow operating activity net earning adjustment reconcile net earning cash flow operating activity depreciation amortization property intangible stock base compensation asset writedown contingent consideration reversal net gain sale assetsbusinesse defer tax provision credit loss account receivable allowance change asset liability net effect acquisition divestiture increasedecrease account receivable increase inventory increase account payable accrue liability increase current noncurrent asset decreaseincrease current noncurrent liability net cash flow operating activity cash flow invest activity addition property plant equipment proceed disposal assetsbusinesse net acquisition net cash acquire note purchase investment sale investment credit support agreement activity net primarily license milestone net cash investing activity cash flow financing activity dividend shareholder repurchase common stock proceed shortterm debt repayment shortterm debt proceed longterm debt net issuance cost repayment longterm debt proceed exercise stock optionsemployee withholding tax stock award net credit support agreement activity net net cash financing activity effect exchange rate change cash cash equivalent increasedecrease cash cash equivalent cash cash equivalent begin year note cash cash equivalent end year note supplemental cash flow datum cash pay year interest interest net capitalize income taxis supplemental schedule noncash investing financing activity treasury stock issue employee compensation stock option plan net cash proceed employee withholding tax stock award conversion debt acquisition fair value asset acquire fair value liability assume noncontrolle interest net cash pay acquisition note note consolidated financial statement note consolidated financial statement summary significant accounting policy principle consolidation consolidated financial statement include account johnson johnson subsidiaries company intercompany account transaction eliminate column row table add round percentage calculate actual nonrounde figure description company business segment company approximately employee worldwide engage research development manufacture sale broad range product healthcare field company conduct business virtually country world primary focus product relate human health wellbee company organize business segment consumer health pharmaceutical medical device consumer health segment include broad range product baby care oral care skin healthbeauty overthe counter pharmaceutical womens health wound care market product market general public sell online ecommerce retail outlet distributor world pharmaceutical segment focus therapeutic area include immunology infectious disease neuroscience oncology pulmonary hypertension cardiovascular metabolic disease product segment distribute directly retailer wholesaler distributor hospitals healthcare professional prescription use medical device segment include broad range product orthopaedic surgery interventional solution cardiovascular neurovascular vision field product distribute wholesaler hospital retailer principally professional field physician nurse hospital eye care professional clinic november company announce intention separate company consumer health business intention create new publicly trade company company target completion plan separation month initial announcement new accounting standard recently adopt accounting standard new material accounting standard adopt fiscal recently issue accounting standard adopt january company assess adoption impact recently issue accounting standard financial accounting standard board company financial statement material update previous assessment company annual report fiscal year end january new material accounting standard issue fiscal impact company asu reference rate reform mid financial conduct authority fca announce long require bank submit rate london interbank offer rate libor market participant work transition alternative reference rate reference rate reform rely libor available end reference rate reform term refer effort undertake regulator market participant introduce new reference rate base large liquid population observable transaction company evaluate implication reference rate reform applicable financial reporting guidance asu reference rate reform topic facilitation effect reference rate reform financial reporting key financial commercial contract reference libor include hedge relationship contract review mature prior termination libor modify apply new reference rate primarily secure overnight financing rate sofr applicable company apply available practical expedient asc scope financial commercial contract previously reference libor applicable result company implementation reference rate reform provision commercial financial contract result material change company cash equivalentsthe company classify highly liquid investment state maturity month date purchase cash equivalent highly liquid investment state maturity great month date purchase current marketable security company policy make investment commercial institution investment grade credit rating company invest cash primarily government security obligation corporate debt security money market fund reverse repurchase agreement rra rra collateralized deposit form government security obligation value company record asset liability company permit sell repledge associate collateral company policy collateral equivalent credit rating company utilize party custodian manage exchange fund ensure collateral receive maintain value rra daily basis rra state maturity great month date purchase classify marketable security investment investment classify hold maturity investment report amortize cost realize gain loss report earning investment classify availableforsale debt security carry estimate fair value unrealize gain loss record component accumulate comprehensive income availableforsale security available current operation classify current asset classify long term management determine appropriate classification investment debt equity security time purchase reevaluate determination balance sheet date company review investment impairment adjust investment fair value earning require property plant equipment depreciation property plant equipment state cost company utilize straightline method depreciation estimate useful life asset building building equipment year land leasehold improvement year machinery equipment year company capitalize certain computer software development cost include machinery equipment incur connection develop obtain computer software internal use capitalize software cost amortize estimate useful life software generally range year company review longlive asset assess recoverability undiscounted cash flow certain event change operate economic condition occur impairment assessment perform recoverability carrying value asset asset determine impair loss measure base difference asset fair value carry value quote market price available company estimate fair value discount value estimate future cash flow revenue recognition company recognize revenue product sale obligation term contract customer satisfy generally occur transfer control good customer company global payment term typically day provision certain rebate sale incentive trade promotion coupon product return discount customer governmental clawback provision account variable consideration record reduction sale liability recognize accrue rebate return promotion consolidate balance sheet product discount grant base term arrangement direct indirect market participant market condition include consideration competitor pricing rebate estimate base contractual term historical experience patient outcome trend analysis project market condition market serve significant portion liability relate rebate sale company pharmaceutical product primarily manage care medicare medicaid program amount billion billion january january respectively company evaluate market condition product group product primarily analysis wholesaler thirdparty sellthrough market research datum internally generate information sale return estimate record base historical sale return information product exhibit unusual sale return pattern date competition marketing matter specifically investigate analyze accounting sale return accrual sale return allowance represent reserve product return expiration destruction field specific area product recall sale return reserve base historical return trend product market percent gross sale accordance company accounting policy company generally issue credit customersfor return good company sale return reserve account accordance gaap guidance revenue recognition right return exist sale return reserve record sale value sale return consumer health pharmaceutical segment exclusively resalable sale return certain franchise medical device segment typically resalable material company infrequently exchange product inventory return product sale return reserve total company approximately annual net trade sale fiscal year promotional program product list allowance cooperative advertising arrangement record period relate sale continue promotional program include coupon volumebase sale incentive program redemption cost consumer coupon base historical redemption experience product value volumebase incentive program base estimate sale volume incentive period record product sell arrangement evaluate determine appropriate amount defer record reduction revenue company earn profitshare payment collaborative arrangement certain product include sale customer year present profitshare payment total revenue include sale customer note consolidated financial statement disaggregation revenue shipping handle shipping handling cost incur billion billion billion fiscal year respectively include sell marketing administrative expense revenue receive shipping handle sale customer period present inventory inventory state low cost net realizable value determine firstin firstout method intangible asset goodwill authoritative literature gaap require goodwill intangible asset indefinite life assess annually impairment company complete annual impairment test fiscal fourth quarter future impairment test perform annually fiscal fourth quarter soon warrant purchase inprocess research development account indefinite live intangible asset underlie project complete point intangible asset account definite live intangible asset abandon point intangible asset write partially impair intangible asset finite useful life continue amortize useful life review impairment warrant economic condition note detail intangible asset goodwill financial instrument require gaap derivative instrument record balance sheet fair value fair value exit price receive sell asset pay transfer liability fair value marketbase measurement determine assumption market participant use price asset liability authoritative literature establish threelevel hierarchy prioritize input measure fair value level high priority level low change fair value derivative record period current earning comprehensive income depend derivative designate hedge transaction type hedge transaction company document relationship hedge item derivative overall risk management strategy include reason undertake hedge transaction enter derivative objective strategy minimize foreign currency exposure impact company financial performance protect company cash flow adverse movement foreign exchange rate ensure appropriateness financial instrument manage enterprise risk associate financial institution note additional information financial instrument lease company determine arrangement lease contract inception establish contract convey right control use identify property plant equipment period time exchange consideration right use rou assets lease liability operating lease include asset accrue liability liability consolidate balance sheet rou asset represent right use underlie asset lease term lease liability represent obligation lease payment arise lease commitment finance lease significant include property plant equipment loan note payable longterm debt consolidate balance sheet rou assets lease liability recognize lease commencement date base present value minimum lease payment lease term company use incremental borrowing rate base informationavailable commencement date determine present value lease payment implicit rate readily determinable lease term include option extend terminate lease option include lease term reasonably certain company exercise option operating lease expense recognize straightline basis lease term company elect follow policy election adoption use portfolio approach lease asset master service agreement exclusion short term lease balance sheet separate lease nonlease component company primarily operate lease space vehicle manufacture equipment datum processing equipment rou asset pertain operating lease billion billion respectively lease liability billion billion respectively operate lease cost billion billion billion respectively cash pay amount include measurement lease liability billion billion billion respectively product liability accrual product liability claim record undiscounted basis probable liability incur liability reasonably estimate base exist information actuarially determine estimate applicable accrual adjust periodically additional information available company accrue estimate legal defense cost need defend matter cost probable reasonably estimate extent adverse verdict render company company record accrual loss determine probable reasonably estimate company self insurance whollyowne captive insurance company addition accrual self insurance program claim exceed insurance coverage accrue loss probable amount reasonably estimate research development research development expense expense incur accordance asc research development upfront milestone payment party connection research development collaboration expense incur point regulatory approval payment party subsequent regulatory approval capitalize amortize remain useful life relate product amount capitalize payment include intangible net accumulate amortization company enter collaborative arrangement typically pharmaceutical biotechnology company develop commercialize drug candidate intellectual property arrangement typically involve party active participant collaboration expose significant risk reward dependent commercial success activity collaboration usually involve activity party include research development marketing selling distribution collaboration require upfront milestone royalty profit share payment contingent occurrence certain future event link success asset development amount collaborative partner relate development activity generally reflect reduction research development expense performance contract development service central company operation general income statement presentation collaboration follow naturetype collaboration statement earning presentation thirdparty sale product profit share payment receive sale customer royaltiesmilestone pay collaborative partner post cost product sell regulatory approval royalty receive collaborative partner income expense net upfront payment milestone pay collaborative partner research development expense preregulatory approval research development payment collaborative partner research development expense research development payment receive reduction research development expense collaborative partner government entity milestone capitalize intangible asset amortize cost product sell useful life year present individual project represent great total annual consolidated research development expense company number product compound develop collaboration strategic partner include xarelto codevelope bayer healthcare imbruvica develop collaboration comarketed pharmacyclic llc abbvie company separately company number license arrangement product compound include darzalex license genmab advertising cost associate advertising expense year incur include sell marketing administrative expense advertising expense worldwide comprise television radio print medium internet advertising billion billion billion fiscal year respectively income taxis income taxis record base amount refundable payable current year include result difference gaap accounting tax reporting record defer tax asset liability company estimate defer tax asset liability base enact tax regulation rate future change tax law rate affect record defer tax asset liability future company unrecognize tax benefit uncertain tax position company follow gaap prescribe recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return management believe change estimate material effect company result operation cash flow financial position united states enact law new tax legislation tax cut job act tcja law include provision comprehensive overhaul corporate income tax code include reduction statutory corporate tax rate effective january tcja include provision tax previously undistribute earning company locate foreign jurisdiction undistribute earning form cash cash equivalent tax rate earning tax rate tax payable year accrue interest payment begin continue remain balance end approximately billion billion classified noncurrent reflect longterm taxis payable company balance sheet balance account relate receivables tax authority expect receive month tcja include provision tax global intangible lowtaxed income gilti gilti describe excess shareholder total net foreign income deem return tangible asset provide tcja january fasb issue guidance allow company elect accounting policy record tax effect gilti period tax liability generate period cost provide defer tax asset liability relate basis difference exist expect effect gilti inclusion future year reversal defer method company elect account gilti defer method defer tax amount record base evaluation temporary difference expect reverse gilti incur future period company record defer tax liability undistribute earning prior december international subsidiary company provide defer taxis undistribute earning subsequent january certain international subsidiary earning consider indefinitely reinveste company intend continue reinvest earning international operation company decide later date repatriate earning company require provide net tax effect amount company estimate tax effect repatriation approximately billion currently enact tax law regulation current currency exchange rate include possible benefit foreign tax credit substantially offset cost note consolidated financial statement information income taxis net earning share basic earning share compute divide net earning available common shareholder weight average number common share outstanding period dilute earning share reflect potential dilution occur security exercise convert common stock treasury stock method use estimate preparation consolidate financial statement conformity accounting principle generally accept require management estimate assumption affect amount report estimate accounting sale discount rebate allowance incentive product liability income taxis withhold taxis depreciation amortization employee benefit contingency intangible asset liability valuation actual result differ estimate company follow provision gaap recording litigation relate contingency liability record loss probable reasonably estimate good estimate loss range accrue estimate range well minimum accrue extent covid impact company business financial result depend numerous evolve factor include limited magnitude duration covid extent impact worldwide macroeconomic condition include interest rate employment rate health insurance coverage speed anticipate recovery governmental business reaction pandemic company assess certain accounting matter generally require consideration forecast financial information context information reasonably available company unknown future impact covid january date report accounting matter assess include limited company allowance doubtful account credit loss inventory relate reserve accrue rebate associate reserve carry value goodwill otherlonglive asset company ongoing vaccine development distribution effort material impact company consolidate financial statement fiscal year end january company future assessment magnitude duration covid factor result material impact company consolidate financial statement future reporting period annual closing date company follow concept fiscal year end sunday nearest end month december normally fiscal year consist week year fiscal year consist week include additional shipping day case fiscal year case fiscal year reclassification certain prior period amount reclassify conform current year presentation cash cash equivalent current marketable security end fiscal year cash cash equivalent current marketable security comprise dollar million current carry unrecognized estimate cash cash marketable loss fair value equivalent security cash nonus sovereign security reverse repurchase agreement corporate debt security money market fund time deposit subtotal security sovereign security corporate debt security subtotal available sale total cash cash equivalent current marketable security dollar million current carry unrecognized estimate cash cash marketable gain fair value equivalent security cash nonus sovereign security reverse repurchase agreement corporate debt security money market fund time deposit subtotal security sovereign security corporate debt security subtotal available sale total cash cash equivalent current marketable security hold maturity investment report amortize cost realize gain loss report earning available sale debt security report fair value unrealize gain loss report net taxis comprehensive income fair value government security obligation corporate debt security estimate quote broker price significant observable input contractual maturity available sale debt security january follow cost basis fair value dollar million year year year year year total debt security company invest excess cash deposit major bank world highquality money market instrument company policy make investment commercial institution investment grade credit rating inventory end fiscal year inventory comprise dollar million raw material supply good process finish good total inventory property plant equipment end fiscal year property plant equipment cost accumulate depreciation dollar million land land improvement building build equipment machinery equipment construction progress total property plant equipment gross accumulate depreciation total property plant equipment net company capitalize interest expense cost construction facility equipment interest expense capitalize fiscal year million million million respectively depreciation expense include amortization capitalize interest fiscal year billion billion billion respectively retirement disposal property plant equipment cost relate amount accumulate depreciation amortization eliminate asset accumulate depreciation account respectively difference net asset value proceed record earning intangible asset goodwill end fiscal year gross net amount intangible asset dollar million intangible asset definite life patent trademark gross accumulate amortization patent trademark net customer relationship intangible gross accumulate amortization customer relationship intangible net intangible asset indefinite live trademark purchase inprocess research development total intangible asset indefinite live total intangible asset net majority comprise customer relationship fiscal company record partial iprd impairment charge billion primarily relate expect development delay general surgery digital robotic platform ottava acquire auris health acquisition impairment charge calculate base revision discount cash flow valuation model reflect delay human procedure approximately year initial acquisition model assumption second half remain reduction drive asset reach commercialization classify definite life goodwill january january allocate segment business follow dollar million consumer health pharmaceutical medical device total goodwill december goodwill relate acquisition currency translationother goodwill january goodwill relate acquisition goodwill relate divestiture currency translationother goodwill january weight average amortization period patent trademark year weight average amortization period customer relationship intangible asset year amortization expense amortizable asset include cost product sell billion billion billion tax fiscal year end january january december respectively intangible asset writedown include income expense net estimate amortization expense approve product tax succeed year approximately dollar million note consolidated financial statement additional detail relate acquisition divestiture fair value measurement company use forward foreign exchange contract manage exposure variability cash flow primarily relate foreign exchange rate change future intercompany product thirdparty purchase material denominate foreign currency company use cross currency interest rate swap manage currency risk primarily relate borrowing type derivative designate cash flow hedge additionally company use interest rate swap instrument manage interest rate risk relate fix rate borrowing derivative designate fair value hedge company use cross currency interest rate swap forward foreign exchange contract designate net investment hedge additionally company use forward foreign exchange contract offset exposure certain foreign currency asset liabilitie forward foreign exchange contract designate hedge change fair value derivative recognize earning offset current earning effect relate foreign currency asset liability company enter derivative financial instrument trade speculative purpose contain credit risk relate contingent feature company maintain credit support agreement csa certain derivative counterpartie establish collateral threshold base respective credit rating netting agreement january total cash collateral pay company csa amount million net relate net investment cash flow hedge ongoing basis company monitor counterparty credit rating company consider credit nonperformance risk low company primarily enter agreement commercial institution investment grade credit rating refer table significant financial asset liability measure fair value contain footnote receivables payable commercial institution january company notional amount outstanding forward foreign exchange contract cross currency interest rate swap interest rate swap billion billion billion respectively january company notional amount outstanding forward foreign exchange contract cross currency interest rate swap billion billion respectively derivative instrument record balance sheet fair value change fair value derivative record period current earning comprehensive income depend derivative designate hedge transaction type hedge transaction designation cash flow hedge entrance date derivative contract inception derivative expect highly effective foreign exchange contract designate cash flow hedge account forward method gainslosse associate contract recognize income statement hedge item impact earning change fair value derivative record accumulate comprehensive income underlie transaction affect earning reclassify earning account hedge transaction gain loss associate interest rate swap change fair value hedge debt attributable change interest rate record interest expense period occur gain loss net investment hedge account currency translation account accumulate comprehensive income portion exclude effectiveness testing record interest income expense spot method ongoing basis company assess derivative continue highly effective offset change hedge item derivative long expect highly effective hedge accounting discontinue company designate euro denominate note issue date range net investment hedge company investment certain international subsidiary use euro functional currency order reduce volatility cause change exchange rate january balance defer net loss derivative include accumulate comprehensive income million aftertax additional information consolidated statement comprehensive income note company expect substantially amount relate forward foreign exchange contract reclassify earning month result transaction expect occur period maximum length time company hedge transaction exposure month exclude interest rate contract net investment hedge ultimately realize earning differ foreign exchange rate change realize gain loss ultimately determine actual exchange rate maturity derivative follow table summary activity relate derivative hedge fiscal year end january january net tax january january cost interest cost interest product income income product income income sale sell expense expense expense sale sell expense expense expense dollar million effect fair value net investment cash flow hedge gain loss fair value hedge relationship interest rate swap contract hedge item derivative designate hedge instrument gain loss net investment hedging relationship cross currency interest rate swap contract gain loss recognize income derivative exclude effectiveness testing gain loss recognize aoci gain loss cash flow hedging relationship forward foreign exchange contract gain loss reclassify aoci income gain loss recognize aoci cross currency interest rate swap contract gain loss reclassify aoci income gain loss recognize aoci january january follow amount record consolidated balance sheet relate cumulative basis adjustment fair value hedge line item consolidate balance cumulative fair value hedge sheet hedge item adjustment include carry include carrying hedge liability hedge liability january january january january dollar million longterm debt follow table effect derivative designate hedge instrument fiscal year end january january location gain loss gainloss recognize income recognize dollar million derivative income derivative derivative designate hedging instrument january january income expense foreign exchange contract follow table effect net investment hedge fiscal year end january january gainloss location gain loss reclassify gainloss reclassify recognize accumulate accumulate oci accumulate oci comprehensive income income income january january january dollars millions january debt interest income expense cross currency interest rate swap interest income expense company hold equity investment readily determinable fair value equity investment readily determinable fair value company measure equity investment readily determinable fair value cost minus impairment plus minus change result observable price change orderly transaction identical similar investment issuer follow table summary activity relate equity investment fiscal year end january january january january change fair sale value reflect non current purchasesother dollar million carry value net income carry value asset equity investment readily determinable value equity investment readily determinable value december january change fair sale value reflect non current purchasesother dollar million carry value net income carry value asset equity investment readily determinable value equity investment readily determinable value record incomeexpense include impact currency fiscal year end january january equity investment readily determinable market value million million respectively change fair value reflect net income result impairment offset impact million million respectively change fair value reflect net income change observable price gain disposal investment impact fiscal drive gain disposal grail investment fair value exit price receive sell asset pay transfer liability fair value marketbase measurement determine assumption market participant use price asset liability accordance asc threelevel hierarchy prioritize input measure fair value level hierarchy describe level high priority level low fair value derivative financial instrument forward foreign exchange contract interest rate contract aggregation currency future cash flow discount present value prevail market interest rate subsequently convert dollar current spot foreign exchange rate company believe fair value derivative instrument materially differ amount realize settlement maturity change fair value material effect company result operation cash flow financial position company hold equity investment classify level debt security classify level company hold acquisition relate contingent liability base certain regulatory commercial event classify level value determine discount cash flow methodology similar technique determination fair value require significant judgment estimation follow level input measure fair value level quote price active market identical asset liability level significant observable input level significant unobservable input company significant financial asset liability measure fair value fiscal year end january january follow dollar million level level level total total derivative designate hedge instrument asset forward foreign exchange contract interest rate contract total liability forward foreign exchange contract interest rate contract total derivative designate hedge instrument asset forward foreign exchange contract liability forward foreign exchange contract available sale investment equity investment debt security liability contingent consideration gross net derivative reconciliation dollar million total gross asset credit support agreement csa total net asset total gross liability credit support agreement csa total net liability summarize information change liabilitie contingent consideration follow dollar million begin balance change estimate fair value addition payment end balance asset liability classify level exception equity investment million classify level contingent consideration million classify level include cross currency interest rate swap interest rate swap classify noncurrent asset classify cash equivalent current marketable security include million million million classified noncurrent liability january january december respectively include million million million classify current liability january january december respectively ongoing fair value adjustment amount record primarily research development expense company record contingent consideration reversal million relate timing certain developmental milestone associate auris health acquisition reversal contingent consideration record income expense note financial asset liability hold carrying consolidate balance sheet borrowing component longterm debt follow effective effective rate rate dollar million note note note note euro euro note debenture note note note euro euro note gbp gbp note note note note note note euro euro note note note debenture note note euro euro note note note debenture note debenture note note note note note note note note subtotal current portion total longterm debt weight average effective rate translation rate january translation rate january excess fair value carry value debt billion end fiscal year billion end fiscal year fair value longterm debt estimate market price corroborate quote broker price significant observable input company access substantial source fund numerous bank worldwide september company secure new day credit facility total credit available company approximate billion expire september interest charge borrowing credit line agreement base term sofr reference rate applicable market rate allow term agreement plus applicable margin commitment fee agreement material fiscal year company continue access liquidity commercial paper market shortterm borrowing current portion longterm debt amount approximately billion billion end fiscal year respectively current portion long term debt billion billion respectively remainder commercial paper local borrowing international subsidiary current debt balance january include billion commercial paper weight average interest rate weight average maturity approximately month aggregate maturity longterm debt obligation commence dollar million income taxis provision taxis income consist dollar million currently payable tax international taxis total currently payable defer taxis international taxis total defer provision taxis income comparison income tax expense statutory rate fiscal year company effective tax rate follow dollar million international earning taxis income tax rate statutory rate international operation tax international income tax benefit loss capital asset tax benefit sharebase compensation tcja relate impact effective rate period present company subsidiary operate puerto rico tax incentive international operation reflect impact operation jurisdiction statutory tax rate different particularly ireland switzerland puerto rico favorable impact effective tax rate compare statutory rate amount include reorganization international subsidiary amount include impact new tax legislation enactment switzerland describe include impact gilti tax foreignderive intangible income deduction foreign income taxable tax code amount include reorganization international subsidiary amount include impact new tax legislation enactment switzerland describe represent impact adjustment balance originally record tcja provisional tax charge information provide fiscal year tax rate decrease compare fiscal year tax rate primarily drive follow item fiscal year company reorganize ownership structure certain whollyowne international subsidiary reorganization company increase tax basis certain asset fair value accordance applicable local regulation net impact restructure approximately billion net benefit benefit company annual effective tax rate comprise follow item approximately billion local defer tax asset record remeasurement tax basis asset fair value benefit reflect international operation company effective tax rate reconciliation approximately billion defer tax expense relate gilti defer tax liability result remeasurement defer tax asset expense reflect tax international income company effective tax rate reconciliation fiscal fourth quarter company recognize loss certain affiliate relate previously impair book value certain intangible reduce tax rate approximately reflect tax benefit loss capital asset effective tax rate reconciliation additionally fiscal impact rate primarily drive litigation acquisition relate item follow company accrue additional legal expense approximately billion talc effective tax rate billion risperdal settlement effective tax rate note consolidated financial statement detail company record partial iprd charge billion ottava intangible asset acquire auris health acquisition effective rate note consolidated financial statement detail fiscal year tax rate decrease compare fiscal year tax rate primarily drive follow item fiscal year switzerland enact federal act tax reform ahv financing traf effective january federal transitional provision traf allow company certain condition adjust tax basis certain asset fair value stepup depreciate amortize result incremental swiss tax deduction transitional periodtraf provide parameter enable swiss canton establish localize tax rate regulation company new cantonal tax parameter include favorable tax benefit patent additional research development tax deduction cantonal transitional provision traf allow company elect tax basis stepup similar federal transition benefit alternative statutory tax rate period exceed year company currently operation locate swiss canton fiscal year describe detail company record impact traf enact period fiscal year final canton company maintain significant operation enact traf legislation additionally company receive ruling swiss federal cantonal tax authority remain jurisdiction significant operation ruling result company revise estimate tax basis adjustment stepup asset result company record additional defer tax benefit company recognize net benefit fiscal year swiss tax reform approximately billion benefit company annual effective tax rate comprise follow item approximately billion tax benefit relate remeasurement swiss defer tax asset liability change federal cantonal tax rate enactment occur fiscal year benefit reflect international operation company effective tax rate reconciliation million defer tax asset relate estimate value federal tax basis stepup company swiss subsidiary asset describe benefit reflect international operation company effective tax rate reconciliation approximately billion defer tax expense relate gilti defer tax liability result remeasurement swiss defer tax asset liability fiscal year benefit reflect tax international income company effective tax rate reconciliation company expect receive future ruling transitional provision traf fiscal year company recognize capital loss certain affiliate relate previously impair book value certain intangible reduce tax rate approximately reflect tax benefit loss capital asset effective tax rate reconciliation addition fiscal year company low income high tax jurisdiction primarily drive impact accrual litigation cost relate talc billion reduce earning taxis effective tax rate accrual additional legal cost include additional billion associate revise agreement principle settle opioid litigation effective tax rate company reduce contingent consideration liability relate auris health acquisition note reverse unrecognized tax benefit completion year tax examination certain jurisdiction fiscal year fiscal year company reorganize ownership structure certain whollyowne international subsidiary fiscal fourth quarter result reduction certain withholding local taxis previously recognize provisional tax cut job act tcja tax charge fiscal year finalize fiscal year follow completion restructuring approval applicable local authority company reverse defer tax liability billion relate defer tax asset billion foreign tax credit net defer tax benefit billion decrease annual effective tax rate benefit reflect tcja relate impact company effective tax rate reconciliation follow item impact fiscal year effective tax rate impact agreement principle settle opioid litigation billion note consolidated financial statement reduce earning taxis effective tax rate decrease company annual effective tax rate approximately december fiscal year treasury issue final foreign tax credit regulation result company revise foreign tax credit initially record fiscal year provisional tcja tax charge result company record increase defer tax asset relate foreign tax credit approximately billion annual effective tax rate benefit reflect tcja relate impact company effective tax rate reconciliation company reassess uncertain tax position relate current irs audit increase unrecognized tax benefit billion liability increase annual effective tax rate approximately sectionon unrecognized tax benefit additional information position relate uncertain tax international transfer pricing expense classify international operation company effective tax rate reconciliation describe swiss tax legislation fiscal year company record net tax expense billion increase effective tax rate fiscal year approximately net tax expense relate federal certain cantonal enactment fiscal year consist follow provision approximately billion tax expense relate remeasurement swiss defer tax asset liability change federal cantonal tax rate enactment occur december expense reflect international operation company effective tax rate reconciliation billion defer tax asset relate estimate value federal tax basis stepup company swiss subsidiary asset benefit reflect international operation company effective tax rate reconciliation approximately million defer tax expense relate gilti defer tax liability result remeasurement swiss defer tax asset liability new defer tax asset federal stepup benefit reflect tax international income company effective tax rate reconciliation temporary difference carryforward end fiscal year follow defer tax defer tax dollar million asset liability asset liability employee relate obligation stock base compensation depreciation property plant equipment goodwill intangible capitalize tax reserve liabilitie income report tax purpose net realizable operating loss carryforward undistribute foreign earning global intangible lowtaxed income miscellaneous international miscellaneous total deferred income taxis certain prior year amount reclassify conform current year presentation inclusive billion defer tax asset establish reorganize ownership structure certain whollyowne international subsidiary previously describe company whollyowne international subsidiary cumulative net loss company believe likely subsidiary generate future taxable income sufficient utilize defer tax asset certain jurisdiction valuation allowance record defer tax asset loss carryforward likely realize valuation allowance material follow table summarize activity relate unrecognized tax benefit dollar million begin year increase relate current year tax position increase relate prior period tax position decrease relate prior period tax position settlement lapse statute limitation end year unrecognize tax benefit billion january recognize affect company annual effective tax rate company conduct business file tax return numerous country currently tax audits progress number tax authority respect united states irs complete audit tax year currently audit tax year fiscal year company final payment approximately billion treasury relate final settlement tax audit liability major jurisdiction company conduct business year remain open tax audit year company believe possible tax audits complete month tax authority jurisdiction outside united states company able provide reasonably reliable estimate time future tax payment relate uncertain tax position company classifie liability unrecognize tax benefit relate interest penalty longterm liability previously note amount relate current united states irs audit interest expense penalty relate unrecognized tax benefit classify income tax expense company recognize tax interest expense million million million fiscal year respectively total accrue interest million million fiscal year respectively employee relate obligation end fiscal fiscal employee relate obligation record consolidated balance sheet dollar million pension benefit postretirement benefit postemployment benefit defer compensation total employee obligation current benefit payable employee relate obligation noncurrent prepay employee relate obligation million million respectively include asset consolidate balance sheet pension benefit plan company sponsor retirement pension plan include define benefit define contribution termination indemnity plan cover employee worldwide company provide postretirement benefit primarily healthcare eligible retire employee dependent international employee cover governmentsponsored program cost company significant nonunion pension benefit employee hire january primarily base employee compensation year retirement number year service final average pay formula pension benefit employee hire calculate different formula base employee compensation total year service retirement value formula january company announce effective january eligible nonunion employee regardless hire date earn benefit retirement value formula amendment affect benefit accrue final average pay formula service january impact change decrease project benefit obligation january approximately billion include amendment line change benefit obligation international subsidiary plan fund deposit trustee annuity purchase group contract reserve provide company fund retiree healthcare benefit advance right modify plan future company december december respectively measurement date international retirement benefit plan net periodic benefit cost company define benefit retirement plan benefit plan include follow component retirement plan benefit plan dollar million service cost interest cost expect return plan asset amortization prior service cost recognize actuarial loss gain curtailment settlement net periodic benefit cost service cost component net periodic benefit cost present line item consolidate statement earning employee compensation cost report include cost product sell research development expense selling marketing administrative expense component net periodic benefit cost present income expense net consolidated statement earning unrecognized gain loss pension plan amortize average remain future service plan plan active employee amortize average life expectancy amortization gain loss benefit plan determine corridor great market value asset accumulate postretirement benefit obligation total unamortized gain loss excess corridor amortize average remain future serviceprior service costsbenefit pension plan amortize average remain future service plan participant time plan amendment prior service costbenefit benefit plan amortize average remain service eligibility age plan participant time plan amendment follow table represent weightedaverage actuarial assumption retirement plan benefit plan worldwide benefit plan net periodic benefit cost service cost discount rate interest cost discount rate rate increase compensation level expect longterm rate return plan asset benefit obligation discount rate rate increase compensation level company discount rate determine consider current yield curve represent high quality longterm fix income instrument result discount rate consistent duration plan liabilitie company methodology determine service interest cost use duration specific spot rate yield curve plan liability cash flow expect rate return plan asset assumption represent company assessment longterm return diversify investment portfolio globally assessment determine projection external financial source longterm historical average actual return asset class asset class allocation market follow table display assume healthcare cost trend rate individual healthcare plan healthcare cost trend rate assume year rate cost trend rate assume decline ultimate trend year rate reach ultimate trend rate follow table set forth information relate benefit obligation fair value plan asset fiscal yearend company define benefit retirement plan postretirement plan retirement plan benefit plan dollar million change benefit obligation project benefit obligation begin year service cost interest cost plan participant contribution amendment actuarial gain loss divestiture acquisition curtailment settlement restructure benefit pay plan effect exchange rate project benefit obligation end year change plan asset plan asset fair value begin year actual return plan asset company contribution plan participant contribution settlement divestiture acquisition benefit pay plan asset effect exchange rate plan asset fair value end year fund status end year amount recognize company balance sheet consist follow noncurrent asset current liability noncurrent liability total recognize consolidated balance sheet end year amount recognize accumulate comprehensive income consist follow net actuarial loss prior service cost credit unrecognized net transition obligation total tax effect accumulate benefit obligation end year january company announce effective january eligible nonunion employee regardless hire date earn benefit retirement value formula amendment affect benefit accrue final average pay formula service january actuarial gain retirement plan primarily relate increase discount rate actuarial loss retirement plan primarily relate decrease discount rate retirement plan benefit plan dollar million amount recognize net periodic benefit cost comprehensive income net periodic benefit cost net actuarial gain loss amortization net actuarial loss prior service cost credit amortization prior service cost credit effect exchange rate total lossincome recognize comprehensive income tax total recognize net periodic benefit cost comprehensive income company plan continue fund qualified plan comply pension protection act international plan fund accordance local regulation additional discretionary contribution deem appropriate meet longterm obligation plan certain plan fund common practice funding provide economic benefit consequently company pension plan fund company contribute million million international pension plan respectively follow table display fund status company qualified nonqualified pension plan international fund unfunded pension plan december december respectively plan international plan qualified plan nonqualifie plan fund plan unfunded plan dollar million plan asset project benefit obligation accumulate benefit obligation fund status project benefit obligation accumulate benefit obligation plan accumulate benefit obligation excess plan asset accumulate benefit obligation project benefit obligation plan asset billion billion billion respectively end billion billion billion respectively end follow table display project future benefit payment companys retirement benefit plan dollar million project future benefit payment retirement plan benefit plan follow table display project future minimum contribution unfunded retirement plan amount include discretionary contribution company elect future dollar million project future contribution pension plan oversee local committee board responsible overall administration investment pension plan determine investment policy strategy goal committee board consider factor include local pension rule regulation local tax regulation availability investment vehicle separate account commingle account insurance fund etc funded status plan ratio active retiree duration liability relevant factor include diversification liquidity local market liquidity base currency majority company pension fund open new entrant expect ongoing plan permit investment primarily liquid andor list little reliance illiquid nontraditional investment hedge fund companys retirement plan asset allocation end target allocation follow percent target plan asset allocation worldwide retirement plan equity security debt security total plan asset determination fair value plan asset plan establish welldocumented process determine fair value fair value base quote market price available list price quote available fair value base model primarily use input marketbase independently source market parameter include yield curve interest rate volatilitie equity debt price foreign exchange rate credit curve plan believe valuation method appropriate consistent market participant use different methodology assumption determine fair value certain financial instrument result different estimate fair value report date valuation hierarchy authoritative literature establish threelevel hierarchy prioritize input measure fair value level hierarchy describe table level high priority level low net asset value nav base value underlie asset own fund minus liability divide number share outstanding financial instrument categorization valuation hierarchy base low level input significant fair value measurement follow description valuation methodology investment measure fair value shortterm investment fund cash quote shortterm instrument value closing price hold deposit custodian bank investment investment vehicle value nav provide administrator fund nav quote price market active classify level government agency security limit number investment value closing price report major market individual security trade quote price available active market investment classify level valuation hierarchy quote market price available specific security fair value estimate pricing model quote price security similar characteristic discount cash flow quote market price security available active market classify level debt instrument limit number investment value closing price report major market individual security trade quote price available active market investment classify level quote market price available specific security fair value estimate pricing model quote price security similar characteristic discount cash flow classify level level debt instrument price base unobservable input equity security equity security value closing price report major market individual security trade substantially equity security classify level valuation hierarchy commingle fund investment vehicle value nav provide fund administratorasset level category quote market price asset asset represent primarily limit partnership investment vehicle value nav provide fund administrator asset exchange list actively trade classified level inactively trade asset classify level follow table set forth retirement plan investment measure fair value december december quote price significant active significant investment market observable unobservable measure net identical asset input input asset value level level level total asset dollar million shortterm investment fund government agency security debt instrument equity security commingle fund asset investment fair value activity level asset significant year present company benefit plan unfunded commingle fund level million million december december respectively fair value johnson johnson common stock directly hold plan asset million total plan asset december million total plan asset december saving plan company voluntary saving plan design enhance exist retirement program cover eligible employee company match percentage employee contribution consistent provision plan heshe eligible total company match contribution plan million million million fiscal year respectively capital treasury stock change treasury stock treasury stock amount million treasury stock share thousand share balance december employee compensation stock option plan repurchase common stock balance december employee compensation stock option plan repurchase common stock balance january employee compensation stock option plan repurchase common stock balance january aggregate share common stock issue approximately share end fiscal year cash dividend pay share fiscal year compare dividend share fiscal year share fiscal year january board director declare regular cash dividend share payable march shareholders record february december company announce board director approve share repurchase program authorize company purchase billion company share common stock share repurchase program complete september accumulate comprehensive income loss component comprehensive income loss consist follow total gain accumulate foreign loss currency gainloss employee derivative comprehensive dollar million translation security benefit plan hedge income loss december net change december net change january net change january amount accumulate comprehensive income present net relate tax impact foreign currency translation adjust income taxis relate permanent investment international subsidiary additional detail comprehensive income consolidated statement comprehensive income detail reclassification accumulate comprehensive income gainloss security reclassification release income expense net employee benefit plan reclassification include net periodic benefit cost note additional detail gainloss derivative hedge reclassification earning record account hedgedtransaction note additional detail international currency translation translation subsidiary operate nonus dollar currency company determine local currency international subsidiary functional currency highly inflationary economy define compound cumulative rate inflation past year substantial portion cash flow local currency majority company subsidiary local currency functional currency consolidate international subsidiary balance sheet currency effect record component accumulate comprehensive income current noncurrent asset line statement cash flow include impact foreign currency translation equity account include result translate certain balance sheet asset liability current exchange rate account historical rate locate highly inflationary economy argentina venezuela translation balance sheet account highly inflationary economy reflect operating result rollforward change fiscal year foreign currency translation adjustment include note net currency transaction gain loss include income expense loss million million million fiscal year respectively earning share follow reconciliation basic net earning share dilute net earning share fiscal year end january january december millions share amount basic net earning share average share outstanding basic potential share exercisable stock option plan share repurchase treasury stock method convertible debt share adjust average share outstanding diluted diluted net earning share dilute net earning share calculation fiscal year include share relate stock option exercise price option average market value company stock january company convertible debt dilute net earning share calculation fiscal year exclude million share relate stock option exercise price option great average market value company stock january company convertible debt dilute net earning share calculation fiscal year exclude insignificant number share relate stock option exercise price option great average market value company stock dilute net earning share calculation fiscal year include dilutive effect convertible debt offset relate reduction interest expense million aftertax common stock stock option plan stock compensation agreement january company stockbase compensation plan share outstanding contract company longterm incentive plan longterm incentive plan longterm incentive plan expire april option restrict share grant subsequent date longterm incentive plan longterm incentive plan company issue million share common stock plus share cancel expire forfeit issue longterm incentive plan subsequent april share available future grant longterm incentive plan million end fiscal year compensation cost charge income plan million million million fiscal year respectively total income tax benefit recognize income statementfor sharebase compensation cost million million million fiscal year respectively company recognize additional income tax benefit million million million fiscal year respectively option exercise restrict share vest total unrecognized compensation cost million million million fiscal year respectively weight average period cost recognize year year year fiscal year respectively sharebase compensation cost capitalize inventory insignificant period company settle employee benefit equity issuance treasury share treasury share replenish market purchase year number share settle employee benefit equity issuances stock option stock option expire year date grant vest service period range month year option grant average high low price company common stock new york stock exchange date grant fair value option award estimate date grant blackschole option valuation model use assumption note follow table grant expect volatility represent blend rate year weekly historical overall volatility rate week average imply volatility rate base atthemoney trade johnson johnson option life year grant historical datum determine expect life option riskfree rate base treasury yield curve effect time grant average fair value option grant fiscal year respectively fair value estimate base weighted average assumption riskfree rate expect volatility expect life year expect dividend yield summary option activity plan january january december change year end date present aggregate weight intrinsic outstanding average exercise value share thousand share price dollar million share december option grant option exercise option canceledforfeite share december option grant option exercise option canceledforfeite share january option grant option exercise option canceledforfeite share january total intrinsic value option exercise million million million fiscal year respectively follow table summarize stock option outstanding exercisable january outstanding exercisable share thousand weight weight average average exercise price range option average life exercise price option exercise price average contractual life remain year stock option outstanding january december average life year average life year respectively stock option exercisable january december average price average price respectively restrict share unit performance share unit company grant restrict share unit vest service period range month year company grant performance share unit pay share johnson johnson common stock end threeyear performance period performance share unit vest vest tie completion service period range month year achievement threeyear period equallyweighte goal directly align help drive longterm total shareholder return operational sale adjust operational earning share relative total shareholder return begin fiscal performance share grant equallyweighte goal directly align help drive longterm total shareholder return adjust operational earning share relative total shareholder return number share actually earn end threeyear period vary base actual performance target number performance share unit grant summary restrict share unit performance share unit activity plan january present outstanding outstanding restricted share performance share unit unit share thousand share january grant issue canceledforfeitedadjuste share january average fair value restrict share unit grant fiscal year respectively fair market value date grant fair value restrict share unit discount dividend pay restricted share unit vest period fair value restrict share unit issue million million million respectively weight average fair value performance share unit grant fiscal year calculate weighted average fair market value component goal date grant fair value sale earning share goal performance share unit estimate date grant fair market value share time award discount dividend pay performance share unit vest period fair value relative total shareholder return goal performance share unit estimate date grant monte carlo valuation model fair value performance share unit issue million million million fiscal year respectively segment business geographic area sale customer change dollar million consumer health otc international worldwide skin healthbeauty international worldwide oral care international worldwide baby care international worldwide woman health international worldwide wound careother international worldwide total consumer health international worldwide pharmaceutical immunology international worldwide remicade exports international worldwide simponi simponi aria international worldwide stelara international worldwide tremfya international worldwide immunology international worldwide infectious disease international worldwide covid vaccine international worldwide edurant rilpivirine international worldwide prezista prezcobix rezolsta symtuza international worldwide infectious disease international worldwide neuroscience international worldwide concerta methylphenidate international worldwide invega sustenna xeplion invega trinza trevicta international worldwide risperdal consta international worldwide neuroscience international worldwide oncology international worldwide darzalex international worldwide erleada international worldwide imbruvica international worldwide zytiga abiraterone acetate international worldwide oncology international worldwide pulmonary hypertension international worldwide opsumit international worldwide uptravi international worldwide international worldwide cardiovascular metabolism international worldwide xarelto international worldwide invokana invokamet international worldwide procrit eprex international worldwide international worldwide total pharmaceutical international worldwide medical device interventional solution international worldwide orthopaedic international worldwide hip international worldwide knee international worldwide trauma international worldwide spine sport international worldwide surgery international worldwide advance international worldwide general international worldwide vision international worldwide contact lense international worldwide surgical international worldwide total medical device international worldwide worldwide international worldwide certain prior year amount reclassify conform current year presentation percentage great meaningful income loss tax identifiable asset dollar million consumer health pharmaceutical medical device total expense allocate segment general corporate worldwide total addition property depreciation plant equipment amortization dollar million consumer health pharmaceutical medical device segment total general corporate worldwide total sale customer longlive asset dollar millions united states europe western hemisphere exclude asiapacific africa segment total general corporate non longlived asset worldwide total note description segment company operate export sale significant fiscal year company utilize wholesaler distribute product segment represent approximately total consolidated revenue fiscal year company wholesaler distribute product segment represent approximately total consolidated revenue fiscal year company wholesaler distribute product segment represent approximately total consolidated revenue amount allocate segment include interest income expense general corporate income expense general corporate include cash cash equivalent marketable security consumer health include litigation expense billion primarily talc related reserve restructure relate charge billion pharmaceutical include litigation expense billion primarily relate risperdal divestiture gain billion gain security billion restructuring relate charge billion medical device include restructure relate charge billion inprocess research development expense billion medical device regulation charge billion litigation expense billion consumer health include litigation expense billion primarily talc related reserve certain settlement pharmaceutical include litigation expense billion primarily relate agreement principle settle opioid litigation unrealize gain security billion restructuring relate charge billion medical device include contingent consideration reversal billion related timing certain developmental milestone associate auris health acquisition litigation expense billion restructuring relate charge billion inprocess research development expense billion medical device regulation charge billion consumer health include gain billion relate company previously hold equity investment cilabo litigation expense billion restructuring relate charge billion pharmaceutical include litigation expense billion billion relate agreement principle settle opioid litigation inprocess research development expense billion relate alio asset research development expense billion upfront payment relate argenx unrealize gain security billion actelion acquisition integration relate cost billion restructuring charge billion medical device include gain billion divestiture asp business restructuring relate charge billion litigation expense billion auris health acquisition integration relate cost billion longlive asset include property plant equipment net fiscal year respectively intangible asset goodwill net fiscal year respectively acquisition divestiture fiscal year company material acquisition fiscal year certain business acquire billion cash billion liability assume acquisition account acquisition method accordingly result operation include financial statement respective date acquisition excess purchase price estimate fair value tangible asset acquire amount billion assign identifiable intangible asset residual record goodwill fiscal year acquisition primarily include right investigational compound bermekimab multiple dermatological indication certain employee xbiotech inc xbiotech momenta pharmaceuticals inc momenta company discover develop novel therapy immunemediate disease outstanding share verb surgical inc company significant robotic datum science capability fiscal quarter company complete acquisition right investigational compound bermekimab multiple dermatological indication certain employee xbiotech inc purchase price billion fair value acquisition allocate primarily nonamortizable intangible asset primarily iprd billion apply probability success factor range reflect inherent development regulatory commercial risk different indication discount rate apply approximately xbiotech eligible receive additional payment receipt certain commercialization authorization transaction account business combination include pharmaceutical segment january subsequent fiscal year additional information efficacy available lead company decision terminate development bermekimab atopic dermatitis company record intangible asset impairment charge approximately billion related inprocess research development asset bermekimab jnj investigational drug treatment hidradenitis suppurativa impairment charge relate indication nonrecognize subsequent event reflect quarter financial statement company acquire right bermekimab xbiotech inc fiscal year additionally fiscal quarter company complete acquisition outstanding share verb surgical inc company significant robotic datum science capability include share previously hold verily transaction account business combination include medical device segment fair value acquisition allocate primarily nonamortizable intangible asset primarily iprd billion goodwill billion asset billion liability assume billion fair value company previously hold equity investment verb surgical inc billion october company complete acquisition momenta purchase price approximately billion net cash acquire fair value acquisition allocate primarily nonamortizable intangible asset iprd billion goodwill billion asset billion liability billion asset acquire intended address substantial unmet medical need maternalfetal disorder neuroinflammatory disorder rheumatology dermatology autoimmune hematology depend asset probability success factor range fair value calculation reflect inherent development regulatory risk iprd discount rate apply approximately goodwill primarily attributable synergy expect arise business acquisition expect deductible tax purpose transaction account business combination include pharmaceutical segment fiscal year certain business acquire billion cash billion liability assume acquisition account acquisition method accordingly result operation include financial statement respective date acquisition excess purchase price estimate fair value tangible asset acquire amount billion hasbeen assign identifiable intangible asset residual record goodwill fiscal year acquisition primarily include cilabo japanese company focus marketing development distribution broad range dermocosmetic cosmetic skincare product auris health inc privately hold developer robotic technology initially focus lung cancer fdacleare platform currently bronchoscopic diagnostic therapeutic procedure january company acquire cilabo japanese company focus marketing development distribution broad range dermocosmetic cosmetic skincare product total purchase price approximately billion equate approximately billion exchange rate japanese yen dollar january additionally fiscal quarter company recognize pretax gain record income expense net approximately billion related company previously hold equity investment cilabo company treat transaction business combination include consumer health segment fiscal quarter company finalize purchase price allocation final fair value acquisition allocate primarily amortizable intangible asset billion goodwill billion liability billion amortizable intangible asset comprise brandtrademark customer relationship weight average life year goodwill primarily attributable synergy expect arise business acquisition expect deductible tax purpose april company complete acquisition auris health inc approximately billion net cash acquire additional contingent payment billion aggregate payable reach certain predetermine milestone auris health privately hold developer robotic technology initially focus lung cancer fdacleare platform currently bronchoscopic diagnostic therapeutic procedure company treat transaction business combination include medical device segment fair value acquisition allocate primarily amortizable nonamortizable intangible asset primarily iprd billion goodwill billion marketable security billion liability assume billion include fair value contingent payment mention goodwill primarily attributable synergy expect arise business acquisition expect deductible tax purpose fiscal second quarter company finalize purchase price allocation fiscal company record income approximately billion reversal contingent consideration relate time certain developmental commercial milestone expect meet base company current timeline fiscal quarter company record partial iprd impairment charge billion relate timing progression digital surgery platform fiscal quarter company record partial iprd charge billion primarily relate expect development delay general surgery digital robotic platform ottava probability success factor range ottava subplatform fair value calculation reflect inherent regulatory commercial risk contingent payment iprd discount rate apply approximately accordance gaap standard relate business combination goodwill intangible asset supplemental pro forma information fiscal year provide impact aforementione acquisition material effect company result operation cash flow financial position divestiture fiscal year separate transaction company divest brand outside pharmaceutical segment company recognize pretax gain record income expense net approximately billion fiscal year company sell million share idorsia ltd idorsia ownership company time transaction result gross proceed approximately chf million million base sale price chf share result immaterial net loss end fiscal company right approximately million share convertible loan principal chf million june fiscal year company convert chf million million loan approximately million share idorsia reflect fair value january fiscal quarter company undrawn credit facility idorsia terminate fiscal year company divest asp business fortive corporation aggregate value approximately billion consist billion cash proceed billion retain net receivables company recognize pretax gain record income expense net approximately billion legal proceeding johnson johnson certain subsidiary involve lawsuit claim product liability intellectual property commercial indemnification matter governmental investigation legal proceeding arise time time ordinary course business ongoing impact covid pandemic certain trial reschedule delay company continue monitor legal proceeding situationevolve person trial resume company record accrual loss contingency associate legal matter probable liability incur loss reasonably estimate january company determine liability associate certain litigation matter probable reasonably estimate company accrue matter continue monitor related legal issue adjust accrual warrant base new information development accordance asc litigation regulatory matter discuss loss probable reasonably possible company unable estimate possible loss range loss amount accrue amount accrue legal contingency result complex series judgment future event uncertainty rely heavily estimate assumption include time relate payment ability estimate judgment affect factor include thing damage seek proceeding unsubstantiated indeterminate scientific legal discovery commence complete proceeding early stage matter present legal uncertainty significant fact dispute procedural jurisdictional issue uncertainty unpredictability number potential claim ability achieve comprehensive multiparty settlement complexity relate crossclaim counterclaim andor numerous party involve extent adverse award judgment verdict render company company record accrual loss determine probable reasonably estimate company opinion base examination matter experience date discussion counsel ultimate outcome legal proceeding net liability accrue company balance sheet expect material adverse effect company financial position resolution increase accrual matter report period material adverse effect company result operation cash flow period product liability johnson johnson certain subsidiary involve numerous product liability claim lawsuit involve multiple product claimant case seek substantial compensatory available punitive damage company believe substantial defense feasible predict ultimate outcome litigation time time substantial defense company consider isolate settlement base variety circumstance company establish accrual product liability claim lawsuit compliance asc base currently available information case limited company accrue estimate legal defense cost need defend matter cost probable reasonably estimate certain matter company accrue additional amount estimate cost associate settlement damage loss product liability accrual represent project product liability thousand claim world different litigation environment different fact pattern change accrual require future additional information available significant case include depuy asr acetabular system depuy asr hip resurfacing system pinnacle acetabular cup system pelvic mesh risperdal xarelto body powder contain talc primarily johnson baby powder invokana ethicon physiomesh flexible composite mesh january united states approximately plaintiff direct claim pende lawsuit injury allegedly depuy asr acetabular system depuy asr hip resurfacing system respect pinnacle acetabular cup system respect pelvic mesh respect risperdal respect xarelto respect body powder contain talc respect invokana respect ethicon physiomesh flexible composite mesh number pende lawsuit expect fluctuate certain lawsuit settle dismiss additional lawsuit file august depuy orthopaedics inc depuy announce worldwide voluntary recall asr acetabular system depuy asr resurfacing system asr hip hip replacement surgery claim personal injury depuy johnson johnson case file federal court united states organize multidistrict litigation united states district court northern district ohio litigation file country outside united states primarily united kingdom canada australia ireland germany india italy november depuy reach agreement courtappointe committee lawyer represent asr hip plaintiff establish program settle claim eligible asr hip patient unite states surgery replace asr hips know revision surgery august depuy reach additional agreement february march extend settlement program include asr hip patient revision surgery august prior february settlement program resolve claim bring resolutionsignificant asr hip litigation activity united states lawsuit united states remain settlement program address litigation outside united states australia class action settlement reach resolve claim majority asr hip patient country canada company reach agreement settle class action file country company continue receive information respect potential additional cost associate recall worldwide basis company establish accrual cost associate united states settlement program asr hiprelated product liability litigation claim personal injury depuy orthopaedics inc johnson johnson collectively depuy relate pinnacle acetabular cup system hip replacement surgery product liability lawsuit continue file company continue receive information respect potential cost anticipate number case case file federal court united states organize multidistrict litigation united states district court northern district texas litigation file state court country outside united states adverse verdict render depuy reverse appeal remand retrial quarter depuy establish united states settlement program resolve case settlement program adverse verdict settle company establish accrual product liability litigation associated pinnacle acetabular cup system relate settlement program claim personal injury ethicon inc ethicon johnson johnson arise ethicons pelvic mesh device treat stress urinary incontinence pelvic organ prolapse company continue receive information respect potential cost additional case case file federal court united states organize multidistrict litigation mdl united states district court southern district west virginia march mdl court enter order closing mdl mdl court remand case trial jurisdiction case originally file additional pelvic mesh lawsuit file remain outside mdl company settled resolve majority united states case estimate cost associate settlement remain case reflect company accrual addition class action individual personal injury case claim seek damage allege injury result ethicon pelvic mesh device commence country outside united states include claim case united kingdom netherlands class action israel australia canada november federal court australia issue judgment finding respect liability relation lead applicant generally relation design manufacture pre postmarket assessment test supply promotion device australia treat stress urinary incontinence pelvic organ prolapse march court issue decision enter damage award lead applicant company appeal decision intermediate appellate court court appeal hear february march court enter judgment dismiss appeal application special leave high court australia file april high court hear oral argument application november special leave refuse bring end appellate process individual case assessment process remain group member claim party currently discussion court determine form mechanism individual case assessment process hearing schedule late february class action canada discontinue result settlement group case agreement resolve israeli class action reach party israeli class action currently negotiate wording term thereof finalize settlement subject court approval party update court status finalization settlement negotiation end february company establish accrual respect product liability litigation associate ethicons pelvic mesh product follow june worldwide market withdrawal ethicon physiomesh flexible composite mesh physiomesh claim personal injury ethicon inc ethicon johnson johnson allege personal injury arising use hernia mesh device case file federal court united states organize multidistrict litigation mdl united states district court northern district georgia multicounty litigation mcl form new jersey state court assign atlantic county case pende new jersey addition matter mdl mcl additional lawsuit pende united states district court southern district ohio mdl polypropylene mesh device manufacture bard inc multiplaintiff lawsuit pende oklahoma state court lawsuit pende outside united states ethicon lead counsel plaintiff enter term sheet resolve approximately physiomesh case cover approximately plaintiff pende mdl mcl time master settlement agreement msa enter september include case mdl mcl deadline trial setting proceeding currently stay pende completion settlement agreement deadline issuance individual allocation amount special master march cost associate propose settlement reflect company accrual postsettlement case physiomesh mdl mcl subject docket control order require early expert report discovery requirement february approximately active case subject order review evaluatedclaim file ethicon johnson johnson allege personal injury arise proceed mesh proceed ventral patch hernia mesh product march new jersey supreme court enter order consolidate case pende new jersey mcl atlantic county superior court additional case file federal state court united states jurisdiction outside united states discovery underway mcl proceeding ethicon johnson johnson subject claim personal injury arise prolene polypropylene hernia system january new jersey supreme court create mcl atlantic county superior court handle case case involve product file federal state court united states company establish accrual respect product liability litigation associate ethicon physiomesh flexible composite mesh proceed mesh proceed ventral patch prolene polypropylene hernia system product claim personal injury janssen pharmaceuticals inc johnson johnson arise use risperdal relate compound indicate treatment schizophrenia acute manic mixed episode associate bipolar disorder irritability associate autism lawsuit primarily file state court pennsylvania california missouri action pende court united states canada product liability lawsuit continue file company continue receive information respect potential cost anticipate number case company successfully defend number case verdict company include verdict october billion punitive damage relate plaintiff trial judge reduce million january september company enter settlement principle counsel represent plaintiff matter substantially outstanding case united states cost associate settlement reflect company accrual claim personal injury arise use xarelto oral anticoagulant janssen pharmaceuticals inc jpi johnson johnson jpis collaboration partner xarelto bayer healthcare certain affiliate case file federal court united states organize multidistrict litigation united states district court eastern district louisiana addition case file state court united states case consolidate state mass tort litigation philadelphia pennsylvania coordinate proceed los angeles california class action lawsuit file canada march jpi johnson johnson announce agreement principle settle xarelto cases united states settlement agreement execute settlement final december settlement fund january resolve majority case pende united states company establish accrual cost associate united states settlement program xarelto relate product liability litigation significant number personal injury claim allege talc cause cancer johnson johnson consumer inc johnson johnson arising use body powder contain talc primarily johnson baby powder number personal injury lawsuit file state federal court united states outside united states continue increase fiscal year talc case previously go trial company obtain number defense verdict verdict company reverse appeal june missouri court appeal reverse affirm july verdict billion ingham johnson johnson app reduce overall award billion application transfer case missouri supreme court subsequently deny june petition certiorari seek review ingham decision united states supreme court deny june company pay award include interest total approximately billion fact circumstance include term award unique ingham decision representative claim bring company company continue believe strong legal ground contest talc verdict appeal notwithstanding company confidence safety talc product certain circumstance company settle case october johnson johnson consumer inc old jjci implement corporate restructure corporate restructuring result restructure old jjci cease exist new entity create ltl management llc north carolina limited liability company ltl debtor royalty llc north carolina limited liability company direct subsidiary ltl ram debtor direct parent johnson johnson consumer inc new jersey company new jjci debtor receive certain old jjcis asset solely responsible talcrelate liability old jjci include liability relate way injury damage allege injury damage sustain incur purchase use exposure talc include talc contain product risk responsibility damage injury liability exclusive remedy isprovided worker compensation statute act talcrelate liability october notwithstanding company confidence safety talc product debtor file voluntary petition united states bankruptcy court western district north carolina charlotte division seek relief chapter bankruptcy code ltl bankruptcy case result ltl bankruptcy case court enter temporary restraining order stay litigation ltl old jjci november north carolina bankruptcy court confirm scope stay issue preliminary injunction prohibiting enjoin commencement prosecution talcrelate claim ltl old jjci new jjci johnson johnson corporate affiliate identify retailer insurance company certain party ltl bankruptcy case transfer united states bankruptcy court district new jersey november court subsequently extend end february claimants file motion dismiss ltl bankruptcy case court commence hearing february motion dismiss extend effectively stay company talcrelate personal injury litigation ltl agree lift automatic stay small number appeal appeal bond file company agree provide funding ltl payment amount bankruptcy court determine owe ltl establishment billion trust furtherance purpose company establish reserve approximately billion connection aforementione trust subsequent fiscal quarter company deconsolidate ltl relate party result bankruptcy filing impact deconsolidation material company party able reach resolution matter relate talc certain amount scenario recently refer testimony ltl bankruptcy proceeding company unable estimate possible loss range loss accrue february company talc supplier imery talc america inc affiliate imery talc vermont inc imerys talc canada inc collectively imery file voluntary petition chapter united states code bankruptcy code united states bankruptcy court district delaware imerys bankruptcy imery bankruptcy relate imeryss potential liability personal injury exposure talcum powder sell imery talc claim bankruptcy imery allege claim company indemnification right joint insurance proceed imery parent imery tort claimants committee tcc future claimants representative fcr collectively plan proponent file plan reorganization plan disclosure statement relate thereto plan proponent file numerous amendment plan disclosure statement hearing plan proponent disclosure statement hold january court enter order approve disclosure statement allow imery proceed solicit vote plan march company vote reject plan opt consensual release plan april plan proponent announce plan receive requisite number accept vote confirm plan company challenge certain impropriety respect portion vote seek disqualify vote october bankruptcy court issue rule deeming thousand vote withdraw improperly vote october imery cancel confirmation hearing plan imery tcc fcr certain imeryss insurer mediation party agree engage mediation july imery commence adversary proceeding company imery bankruptcy imery adversary proceeding imerys adversary proceeding seek thing certain declaration respect indemnification obligation allegedly owe company imery tcc fcr simultaneously file motion temporary restraining order preliminary injunction seek enjoin company undergo corporate restructuring separate company talc liability asset bankruptcy court deny motion company file motion dismiss adversary proceeding bankruptcy court decide motion dismiss october company file notice bankruptcy filing stay proceeding clarify automatic stay arise file ltl bankruptcy case apply imery adversary proceeding june cyprus mines corporation parent cyprus own certain imery talc mine file adversary proceeding company imery imery bankruptcy seek declaration indemnity right certain contractual agreement cyprus adversary proceeding company deny indemnification owe file motion dismiss adversary complaint february cyprus file voluntary petition relief chapter bankruptcy code file disclosure statement plan plan contemplate settlement imery talc claimants cyprus monetary contribution trust establish imery plan exchange injunction talc claim assert cyprus seek approval disclosure statement plan cyprus tcc fcr appoint cyprus chapter case agree participate mediation mediation party october company file notice bankruptcy filing stay proceeding clarify automatic stay arise file ltl bankruptcy case apply cyprus adversary proceeding february company insurer involve coverage litigation new jersey state court coverage action file motion imery bankruptcy court proceeding seek determination automatic stay apply coverage action alternative seek relief automatic stay allow continue litigatetheir claim coverage action march company file limited response reservation right respect motion court enter agree order modify stay allow litigation coverage action continue october ltl file notice bankruptcy filing stay proceeding clarify automatic stay arise file ltl bankruptcy case apply coverage action february security class action lawsuit file johnson johnson certain name officer united states district court district new jersey allege johnson johnson violate federal security law fail disclose alleged asbestos contamination body powder contain talc primarily johnson baby powder purchaser johnson johnson share suffer loss result plaintiff seek damage april company move dismiss complaint briefing motion complete august december court deny motion dismiss march company answer complaint april briefing plaintiff motion class certification complete july company file notice supplemental authority opposition plaintiff motion class certification plaintiff file response december company file motion supplement class certification record january plaintiff respond discovery ongoing june shareholder file complaint initiate summary proceed new jersey state court book record inspection august johnson johnson respond book record complaint file cross motion dismiss september plaintiff reply court hear oral argument february court grant johnson johnson cross motion dismiss october december january shareholder file separate derivative lawsuit johnson johnson nominal defendant current director certain officer defendant united states district court district new jersey allege breach fiduciary duty relate alleged asbestos contamination body powder contain talc primarily johnson baby powder johnson johnson suffer damage result allege breach february case consolidate single action caption johnson johnson talc stockholder derivative litigation july report deliver company board director independent counsel retain board investigate allegation derivative lawsuit series shareholder letter board receive raise similar issue demand suit bring certain director shareholder send demand plaintiff johnson johnson talc stockholder derivative litigation independent counsel recommend company reject shareholder demand step necessary appropriate secure dismissal derivative lawsuit board unanimously adopt recommendation independent counsel report october shareholder file consolidated complaint january johnson johnson move dismiss consolidated complaint march plaintiff file motion discovery court temporarily terminate johnson johnson motion dismiss pende decision plaintiff motion discovery november court request party submit supplemental briefing plaintiff motion discovery january erisa class action lawsuit file participant johnson johnson savings plan johnson johnson pension benefit committee certain name officer united states district court district new jersey allege defendant breach fiduciary duty offer johnson johnson stock johnson johnson savings plan investment option imprudent failure disclose alleged asbestos contamination body powder contain talc primarily johnson baby powder plaintiff seek damage injunctive relief september defendant file motion dismiss april court grant defendant motion grant leave amend june plaintiff file amend complaint july defendant move dismiss amend complaint october briefing defendant motion complete february court grant defendant motion grant plaintiff leave amend april plaintiffs informed court intend file amend complaint court dismiss case prejudice plaintiff file notice appeal circuit july plaintiff file open brief circuit september defendant file response brief october plaintiff file reply brief january circuit hear oral argument lawsuit bring company superior court california county san diego allege violation california consumer legal remedy act clra relate johnson baby powder lawsuit plaintiff allege johnson johnson violate clra fail provide require proposition warning july company file notice removal united states district court southern district california plaintiff file second amend complaint shortly october company move dismiss second amend complaint failure state claim relief grant response motion plaintiff file amend complaint december company move dismiss amend complaint failure state claim relief grant april court grant motion dismiss grant leave amend plaintiff file fourth amend complaint indicate file motion leave file fifth amend complaint plaintiff file fifth amend complaint august company move dismiss fifth amend complaint failure state claim relief grant january court issue order opinion ruling company favor grant motion dismiss prejudice february plaintiff file notice appeal ninth circuit plaintiff file open brief july company file responsive brief october october notice suggestion bankruptcy file ninth circuit bankruptcy stay impose december court hold reply deadline abeyancein addition company receive inquiry subpoena request produce document talc matter include senator murray member senate committee health education labor pensions department justice subcommittee economic consumer policy house committee oversight reform senate committee judiciary house committee oversight reform individual member congress company produce document respond inquiry continue cooperate government inquiry claim personal injury number johnson johnson company include janssen pharmaceuticals inc johnson johnson arising use invokana prescription medication indicate improve glycemic control adult type diabete december lawsuit file federal court united states organize multidistrict litigation united states district court district new jersey case file state court class action lawsuit file canada product liability lawsuit continue file company continue receive information respect potential cost anticipate number case company settled resolve case claim united states cost associate settlement reflect company accrual claim personal injury number johnson johnson company include janssen pharmaceuticals inc johnson johnson arising use elmiron prescription medication indicate relief bladder pain discomfort associate interstitial cystitis lawsuit allege elmiron contribute development permanent retinal injury vision loss file state federal court united states december lawsuit file federal court unite states include putative class action case seek medical monitoring organize multidistrict litigation united states district court district new jersey case file state court addition class action lawsuit file canada product liability lawsuit continue file company continue receive information respect potential cost anticipate number case company establish accrual defense cost associate elmiron related product liability litigation intellectual property certain subsidiary johnson johnson subject time time legal proceeding claim relate patent trademark intellectual property matter arise business matter involve challenge coverage andor validity patent product allegation certain company product infringe patent party subsidiary believe substantial defense challenge allegation respect significant patent assurance outcome matter loss case adversely affect ability subsidiary sell product result loss sale loss market exclusivity require payment past damage future royalty result noncash impairment charge associate intangible asset significant matter describe medical device december ford albritton sued acclarent inc acclarent united states district court northern district texas allege acclarent relieva spin relievea spinplus product infringe patent albritton allege breach contract fraud true owner acclarent patent trial begin october shortly party reach agreement settle case plaintiff motion dismiss prejudice file october case dismiss prejudice november august intuitive surgical inc intuitive surgical operation inc collectively intuitive file patent infringement suit auris health inc auris united states district court district delaware suit intuitive allege willful infringement patent nos base auris monarch platform auris file ipr petition patent trademark office uspto patent intuitive subsequently drop patent suit december uspto institute review patent deny review patent february march uspto institute review patent deny review patent december uspto declare challenge claim patent invalid intuitive appeal decision march uspto rule challenge claim patent invalid auris appeal decision auris file request reexamination patent november january uspto grant reexamination request trial schedule begin january august rsb spine llc rsb spine file patent infringement suit depuy synthes inc united states district court district delaware october rsb spine amend complaint change name defendant depuy synthes sales inc depuy synthes products inc suit rsb spine allege willful infringement united states patent nos follow product zeropva spacer zerop spacer zerop natural plate synfix spacer synfix evolution system rsb spine seek monetary damage injunctive relief november suit consolidated pretrial purpose patent infringement suit bring rsb spine united states district court district delaware life spine inc medacta usa inc precision spine inc stay enter pende inter parte review patent trademark office lift trial schedule begin december march osteoplastics llc file patent infringement suit depuy synthes inc depuy synthes products inc medical device business services inc synthes inc collectively depuy synthes united states district court district delaware suit osteoplastic allege willful infringement patent nos base proplan cmf virtual surgical planning service trumatch cmf personalize solution april osteoplastic file amend complaint substitute patent patent osteoplastic seek monetary damage injunctive relief june depuy synthes file motion dismiss complaint october court dismiss medical device business services inc case deny motion june osteoplastic admit proplan cmf virtual surgical planning service infringe assert patent trial schedule october october case settle dismiss october rasmussen instruments llc rasmussen file patent infringement suit depuy synthes products inc depuy synthes sales inc medical device business services inc collectively depuy united states district court district massachusetts rasmussen allege depuy willfully infringe patent nos make selling attune balanced sizer april rasmussen seek permission amend infringement contention allege depuy willfully infringe patent making sell attune balancing block rasmussen seek treble damage willful infringement trial schedule february pharmaceutical litigation filer abbreviate new drug application anda follow summarize lawsuit company subsidiary bring generic company file anda fda undertake similar regulatory process outside united states seek market generic form product sell subsidiary johnson johnson prior expiration applicable patent cover product anda typically include allegation noninfringement invalidity applicable patent event company subsidiary successful action automatic statutory stay andas expire united states district court ruling obtain generic company involve ability approval fda introduce generic version product market result potential substantial market share revenue loss applicable product result noncash impairment charge associate intangible asset addition time time company subsidiary settle type action settlement involve introduction generic version product issue market prior expiration relevant patent inter part review ipr process uspto created america invents act time generic company conjunction anda lawsuit challenge applicable patent zytiga begin january janssen inc janssen oncology inc collectively janssen initiate statement claim section patent medicine notice compliance regulations canada apotex inc apotex pharmascience inc pharmascience reddys laboratories ltd reddys laboratories inc collectively drl response party file abbreviate new drug submission and seek approval market generic version zytiga expiration canadian patent trial action conclude november court issue decision hold patent invalid january february janssen appeal decision xarelto march janssen pharmaceuticals inc jpi bayer pharma bayer collectively bayer file patent infringement lawsuit united states district court district delaware lupin limited lupin pharmaceuticals inc file anda seek approval market generic version xarelto expiration patent jpi bayer file patent infringement lawsuit united states district court district delaware reddys laboratories inc reddys laboratories ltd file anda seek approval market generic version xarelto expiration patent july jpi bayer file patent infringement lawsuit united states district court district delaware taro pharmaceutical industry ltd taro pharmaceuticals usa inc collectively taro file anda seek approval market generic version xarelto expiration patent july jpi bayer file patent infringement lawsuit united states district court district delaware teva pharmaceuticals usa inc teva pharmaceutical industries ltd file anda seek approval market generic version xarelto expiration patent august court enter joint stipulation dismiss teva pharmaceutical industries ltd october court consolidated delaware lawsuit purpose include trial trial consolidated delaware lawsuit schedule begin july jpi bayer file patent infringement lawsuit united states district court northern district west virginia mylan pharmaceuticals inc mylan inc file anda seek approval market generic version xarelto expiration patent august jpi bayer file motion united states judicial panel multidistrict litigation mdl panel transfer lawsuit united states district court district delaware coordinate consolidated pretrial proceeding december mdl panel grant motion trial date set lawsuit lawsuit jpi bayer seek order enjoin defendant market generic version xarelto expiration patent invokana invokamet invokamet october janssen pharmaceuticals inc janssen research development llc cilag gmbh international janssen pharmaceutica collectively janssen mitsubishi tanabe pharma corporation mtpc initiate patent infringement lawsuit united states district court district new jersey reddys laboratories inc reddys laboratories ltd drl file anda seek approval market generic version invokamet expiration mtpcs united states patent relate invokamet january janssen mtpc file patent infringement lawsuit united states district court district new jersey macleods pharmaceuticals ltd macleods pharma usa inc macleod file anda seek approval market generic version invokamet expiration mtpcs united states patent nos andor relate invokamet lawsuit janssen mtpc seek order enjoin defendant marketing generic version invokamet andor invokamet expiration relevant patent october janssen inc janssen pharmaceutica mtpc initiate statement claim section patent medicine notice compliance regulation sandoz canada inc sandoz canada response sandozs file and seek approval market generic version invokana expiration canadian patent nos janssen inc janssen pharmaceutica mtpc seek order enjoin sandoz market generic version invokana expiration relevant patent trial schedule begin august opsumit janssen inc janssen actelion pharmaceuticals ltd actelion initiate statement claim section patent medicine notice compliance regulation sandoz canada inc sandoz canada response sandozs file and seek approval market generic version opsumit expiration canadian patent trial ongoing janssen actelion initiate statement claim section patent medicine notice compliance regulation apotex inc apotex canada response apotexs filing and seek approval market generic version opsumit expiration patent trial schedule begin february july janssen actelion initiate statement claim section patent medicine notice compliance regulation jamp pharma corporation jamp canada response jamp file and seek approval market generic version opsumit expiration patent canadian patent trial schedule begin april canadian action janssen actelion seek order enjoin defendant market generic version opsumit expiration relevant patent invega sustenna january janssen pharmaceutica janssen pharmaceuticals inc collectively janssen initiate patent infringement lawsuit united states district court district new jersey teva pharmaceuticals usa inc teva file anda seek approval market generic version invega sustenna expiration united states patent trial conclude october october court issue decision janssen favor teva appeal decision august janssen initiate patent infringement lawsuit united states district court district new jersey mylan laboratories limited mylan file anda seek approval market generic version invega sustenna expiration patent pursuant agreement party judgment favor janssen enter december mylan file appeal december janssen initiate patent infringement lawsuit united states district court district new jersey delaware pharmascience inc mallinckrodt plc specgx llc collectively pharmascience file anda seek approval market generic version invega sustenna expiration patent november janssen initiate patent infringement lawsuit united states district court district delaware tolmar inc tolmar therapeutics inc tolmar pharmaceuticals inc tolmar holding inc collectively tolmar file anda seek approval market generic version invega sustenna expiration patent lawsuit janssen seek order enjoin defendant marketing generic version invega sustenna expiration relevant patent february janssen inc janssen pharmaceutica collectively janssen canada initiate statement claim section patent medicine notice compliance regulation teva canada limited teva canada response tevas filing and seek approval market generic version invega sustenna expiration canadian patent nos janssen subsequently discontinue portion lawsuit relate patent canadian federal court issue public judgment reason declare teva canadas generic version invega sustenna approve infringe certain claim patent claim patent invalid obviousness teva canada appeal november janssen canada initiate statement claim section patent medicine notice compliance regulations pharmascience inc response pharmascience inc file and seek approval market generic version invega sustenna expiration patent summary trial issue infringement take place november january court issue decision favor janssen issue infringement trial issue validity schedule begin july january janssen canada initiate statement claim section patent medicine notice compliance regulation apotex inc apotex response apotexs filing and seek approval market generic version invega sustenna expiration patent summary trial issue infringement take place december january court issue decision favor janssen issue infringement apotex contest validity canadian lawsuit janssen canada seek order enjoin defendant marketing generic version invega sustenna expiration relevant patent invega trinza september janssen pharmaceuticals inc janssen pharmaceutica janssen research development llccollectively janssen initiate patent infringement lawsuit united states district court district new jersey mylan laboratories limited mylan pharmaceuticals inc mylan institutional llc collectively mylan mylan file anda seek approval market generic version invega trinza expiration united states patent relate invega trinza janssen seek order enjoin mylan marketing generic version invega trinza expiration patent trial schedule begin october august janssen initiate patent infringement lawsuit united states district court district new jersey mylan mylan file anda seek approval market generic version invega trinza expiration patent janssen seek order enjoin mylan marketing generic version invega trinza expiration patent october janssen initiate patent infringement lawsuit united states district court district new jersey mylan mylan file anda seek approval market generic version invega trinza expiration patent janssen seek order enjoin mylan marketing generic version invega trinza expiration patent january court consolidate case case file september imbruvica march pharmacyclics llc pharmacyclic janssen biotech inc jbi file patent infringement lawsuit united states district court district delaware alvogen pine brook llc natco pharma ltd collectively alvogen file anda seek approval market generic version imbruvica tablet assert infringement united states patent nos june pharmacyclics jbi amend complaint alvogen allege infringement united states patent pharmacyclic jbi seek order enjoin defendant market generic version imbruvica expiration relevant patent trial alvogen take place october august district court issue decision favor pharmacyclic janssen finding assert claim alvogen infringe invalid alvogen appeal decision september pharmacyclic janssen inc janssen canada initiate statement claim section patent medicine notice compliance regulation natco pharma canada inc natco response natcos file andss seek approval market generic version imbruvica capsule expiration canadian patent nos trial schedule begin july pharmacyclic janssen seek order enjoin natco marketing generic version imbruvica expiration relevant patent uptravi april actelion pharmaceuticals ltd actelion nippon shinyaku ltd nippon shinyaku initiate patent infringement lawsuit united states district court district new jersey zydus pharmaceuticals usa inc zydus worldwide dmcc collectively zydus file anda seek approval market generic version uptravi expiration nippon shinyakus united states patent nos relate uptravi actelion exclusive licensee patent january actelion nippon shinyaku zydus enter confidential settlement agreement lawsuit dismiss government proceeding like company pharmaceutical consumer health medical devices industry johnson johnson certain subsidiary subject extensive regulation national state local government agency united states country operate regulation basis government investigation litigation significant litigation bring investigation conduct government agency list possible criminal charge substantial fine andor civil penalty damage result government investigation litigation average wholesale price awp litigationjohnson johnson pharmaceutical subsidiary awp defendant numerous pharmaceutical company name defendant series lawsuit state federal court involve allegation pricing market certain pharmaceutical product amount fraudulent actionable conduct thing company allegedly report inflated average wholesale price awp drug issue payor allege awps calculate provider reimbursement level plaintiff case include class private person entity pay portion purchase drug issue base awp state government entity medicaid payment drug issue base awp case federal action state action remove federal court consolidated pretrial purpose multidistrict litigation united states district court district massachusetts claim awp defendant ultimately dismiss awp defendant prevail case bring commonwealth pennsylvania awp case resolve court order settlement case bring illinois settle trial new jersey putative class action base awp allegation pende centocor inc ortho biotech inc janssen biotech inc johnson johnson alza corporation case resolve opioid litigation begin continue present johnson johnson janssen pharmaceuticals inc jpi pharmaceutical company name approximately lawsuit relate marketing opioid include duragesic nucynta nucynta suit raise allegation relate previously own active pharmaceutical ingredient supplier subsidiary tasmanian alkaloid pty ltd noramco inc subsidiary divest majority case file state local government similar lawsuit file private plaintiff organization include limited follow individual plaintiff behalf child suffer neonatal abstinence syndrome hospital health insurerspayor date complaint pharmaceutical manufacturer include johnson johnson jpi file state attorney general arkansas florida idaho illinois kentucky louisiana mississippi missouri nevada new hampshire new jersey new mexico new york ohio oklahoma south dakota texas washington west virginia complaint manufacturer file state federal court city county local government agency follow states alabama arizona arkansas california colorado connecticut delaware florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah vermont virginia washington west virginia wisconsin wyoming government puerto rico file suit superior court san juan case pende state court close federal case coordinate federal multidistrict litigation mdl pende district court northern district ohio addition province british columbia file suit johnson johnson canadian affiliate janssen inc industry member canada seek action certify opt class action behalf provincialterritorial federal government canada additional propose class action file canada johnson johnson janssen inc industry member behalf people opioid personal injury municipality nation band october antitrust complaint file private plaintiff federal court tennessee pende transfer mdl action allege variety claim relate opioid marketing practice include false advertising unfair competition public nuisance consumer fraud violation deceptive act practice false claim unjust enrichment suit generally seek penalty andor injunctive monetary relief suit plaintiff seek joint liability defendant adverse judgment lawsuit result imposition large monetary penalty significant damage include punitive damage cost abatement substantial fine equitable remedy sanction trial matter file oklahoma attorney general result judgment johnson johnson jpi million johnson johnson jpi appeal judgment november oklahoma supreme court reverse trial court judgment october johnson johnson jpi announce settlement case set trial mdl county ohio april california counties city oakland commence trial california state court johnson johnson jpi affiliates pharmaceutical manufacturer trial conclude october december court enter final trial judgment favor defendant claim february plaintiff motion set aside vacate judgment deny august johnson johnson receive grand jury subpoena united states attorney office eastern district new york document relate company antidiversion policy procedure distribution opioid medication company understand broad investigation manufacturer distributor monitor program report control substance act september johnson johnson receive subpoenas new york state department financial service nydfs industrywide inquiry effect opioid prescription new york health insurance premium september company learn nydfs file statement charge related investigation june company jpi announce settlement agreement state new york participatingsubdivision include nassau county suffolk county resolve opioidrelate claim company term consistent company previously announce agreement principle contribute billion allin settlement opioidrelate claim state city county tribal government settlement provide new york participate subdivision million address opioidrelate issue reimburse attorney fee cost remove company janssen multidefendant trial opioidrelate claim commence suffolk county june exchange company jpi receive release claim assert new york participate party include nydfs october company jpi announce settlement agreement state texas participate subdivision include dallas county bexar county tarrant county resolve opioidrelate claim company term consistent company previously announce agreement contribute billion allin settlement opioidrelate claim state city county tribal government settlement provide texas participate subdivision million address opioidrelate issue reimburse attorney fee cost remove company janssen multidefendant bellwether trial opioidrelate claim schedule commence texas state courts early exchange company jpi receive release claim assert texas participate subdivision johnson johnson jpi pharmaceutical company receive subpoena request information relate opioids marketing practice follow state attorney general alaska indiana montana new hampshire south carolina tennessee texas washington september johnson johnson jpi contacted texas colorado attorney general office behalf approximately state multistate attorney general investigation october company announce propose agreement principle include company pay billion settlement matter october company agree contribute additional billion allin settlement resolve opioid lawsuit file future claim state city county tribal government total billion accrue subject condition agreement finalize agreement principle admission liability wrongdoe july company announce term agreement settle state subdivision claim finalize onethird allin settlement expect pay month depend level participation state subdivision term provide period time state elect participate agreement period subdivision participate state optin january state territory district columbia elect participate settlement subdivision optin period expire january company retain right optout agreement late february sole discretion insufficient participation base expect participation company commit advance proceed settlement participate state new york texas florida nevada new mexico tribal government case schedule trial june december companys board director receive series shareholder demand letter allege breach fiduciary duty relate marketing opioid board retain independent counsel investigate allegation demand april independent counsel deliver report board recommend company reject shareholder demand step necessary appropriate secure dismissal relate derivative litigation board unanimously adopt recommendation independent counsel report november shareholder send demand file derivative complaint johnson johnson nominal defendant certain current director officer defendant superior court new jersey complaint allege breach fiduciary duty relate marketing opioid johnson johnson suffer damage result allege breach shareholder file amend complaint challenging board rejection demand august johnson johnson move dismiss amend complaint february court hold oral argument johnson johnsons motion february court grant johnson johnsons motion dismiss amend complaint august shareholder send demand file separate derivative complaint court make similar allegation october court grant defendant request reassign secondfile case division firstfile case pende december additional shareholder send demand file separate derivative complaint make similar allegation johnson johnson nominal defendant certain current director officer defendant united states district district new jersey april federal case consolidate single action caption johnson johnson opioid stockholder derivative litigation july shareholder file consolidated complaint september johnson johnson move dismiss consolidate complaint december shareholder oppose johnson johnsons motion johnson johnson file reply february july additional shareholder send demand file derivative complaint federal court make similar allegation defendant name consolidated action january pursuant order consolidate action case consolidated consolidated action february court grant shareholder motion voluntarily dismiss consolidated action prejudice shareholder counsel file notice association firstfile derivative action pende superior court new jerseyother august depuy orthopaedics inc depuy inc know depuy synthes inc johnson johnson services inc collectively depuy receive informal request united states attorney office district massachusetts civil division united states department justice united states production material relate depuy asr hip device july united states notify united states district court district massachusetts decline intervene qui tam case file pursuant false claim act company concern hip device february district court grant company motion dismiss prejudice unseal qui tam complaint deny qui tam relator request leave file amend complaint qui tam relator appeal case united states court appeal circuit july circuit affirm district court dismissal reverse affirm decision deny relator request file amend complaint march depuy file motion strike dismiss relator second amend complaint district court deny depuy motion strike dismiss july depuy file motion reconsideration district court july ruling november district court grant depuy motion reconsideration dismiss case prejudice district court order unseal december relator file postdismissal motion include january omnibus motion reconsideration follow district court order dismiss case prejudice depuy file december motion seek recovery attorney fee october johnson johnson contact california attorney general office multistate attorney general investigation market surgical mesh product hernia urogynecological purpose johnson johnsons subsidiary ethicon inc ethicon california washington file civil complaint johnson johnson ethicon ethicon llc allege violation consumer protection statute similar complaint file company follow states kentucky mississippi west virginia oregon april johnson johnson ethicon settle washington case california case start trial july conclude september october johnson johnson ethicon settle multistate investigation state district columbia january court california issue statement decision find favor state california award civil penalty million april court california deny company motion new trial august court enter judgment respect penalty million deny attorney general request injunctive relief company appeal penalty judgment april company settle west virginia case october company settle attorney general oregon trial kentucky matter schedule june mississippi attorney general file complaint chancery court judicial district hind county mississippi johnson johnson johnson johnson consumer companies inc know johnson johnson consumer inc collectively jjci complaint allege jjci violate mississippi consumer protection act fail disclose allege health risk associate female consumer use talc contain johnson baby powder johnson shower shower product divest seek injunctive monetary relief johnson johnson jjci move summary judgment ground state claim bar preemption trial court deny mississippi supreme court grant johnson johnson jjcis request file interlocutory appeal denial motion summary judgment late brief oral argument complete court reject interlocutory appeal april remand matter trial court state move trial set jjci object trial set ltl bankruptcy decision stay apply defer ltl bankruptcy court state oppose stay argue trial court decide issue concern stay motion trial set jjcis objection hear november january court grant plaintiff motion trial set direct party consult court administrator secure trial date process underway august jjci file petition writ certiorari united states supreme court mississippi supreme court rule april state respond petition writ certiorari november jjci file reply november united states supreme court deny petition writ certiorari december january state new mexico file consumer protection case allege company deceptively market sell talcum powder product make misrepresentation safety product presence carcinogen include asbestos state new mexico file amend complaint march company move dismiss certain claim amend complaint grant company file motion partial judgment pleading december deny company document production february discovery currently schedule close april fortytwo states district columbia commence joint investigation company market talcum powder product time multistate group assert claim company state issue civil investigative demand seek document information company produce document arizona north carolina texas washington enter confidentiality agreement company receive follow request state march janssen pharmaceuticals inc jpi receive civil investigative demand united states attorney office southern district new york relate jpis contractual relationship pharmacy benefit manager period january present regard certain jpis pharmaceutical product demand issue connection investigation false claim act company provide document response demand july johnson johnson janssen products serve qui tam complaint pursuant false claim act file united states district court district new jersey allege offlabel promotion hiv product prezista intelence antikickback violation connection promotion product complaint file seal december federal state government decline intervene lawsuit prosecute relator court deny summary judgment claim december daubert motion grant deny january case proceed trial march janssen biotech inc jbi receive civil investigative demand united states department justice false claim act investigation concern management advisory service provide rheumatology gastroenterology practice purchase remicade simponi aria august united states department justice notify jbi closing investigation subsequently united states district court district massachusetts unseal qui tam false claim act complaint serve company department justice decline intervene qui tam lawsuit august company file motion dismiss grant deny discovery underway april september johnson johnson receive subpoenas united states attorney district massachusetts seek document broadly relate pharmaceutical copayment support program darzalex olysio remicade simponi stelara zytiga subpoena seek document relate average manufacturer price good price reporting center medicare medicaid services relate product rebate payment state medicaid agencies company provide document response subpoenas june johnson johnson receive subpoena united states attorney office district massachusett seek information practice pertain sterilization depuy synthe incdepuy spinal implant hospital boston interaction employee company subsidiary physicians hospitals johnson johnson depuy produce document response subpoena fully cooperate government investigation july public prosecution service rio janeiro representatives brazilian antitrust authority cade inspect office company include johnson johnson brasil indstria comrcio produtos para sade ltda authority appear investigate allegation possible anticompetitive behavior possible improper payment medical device industry company continue respond inquiry foreign corrupt practice act united states department justice united states securities exchange commission time time company receive request variety united states congressional committee produce information relevant ongoing congressional inquiry policy johnson johnson cooperate inquiry produce request information general litigation march april putative class action complaint file contact lens patient number court united states johnson johnson vision care inc jjvci contact lens manufacturer distributor retailer allege vertical horizontal conspiracy fix retail price contact lense complaint allege manufacturer reach agreement certain distributor retailer concern price contact lense sold consumer plaintiff seek damage injunctive relief class action case transfer united states district court middle district florida june plaintiff file consolidated class action complaint november discovery pretrial motion practice complete trial isschedule begin march begin september multiple purport class action file behalf indirect purchaser remicade johnson johnson janssen biotech inc collectively janssen allege janssen violate federal antitrust law contract strategy remicade case consolidated pretrial purpose remicade antitrust litigation united states district court eastern district pennsylvania consolidated complaint seek damage injunctive relief discovery ongoing june walgreen kroger file antitrust complaint johnson johnson janssen biotech inc collectively janssen united states district court eastern district pennsylvania complaint allege janssen violate federal antitrust law contract strategy remicade complaint seek damage injunctive relief march summary judgment grant favor janssen february united states court appeal circuit reverse district court decision matter settle january june united states federal trade commission ftc issue civil investigative demand johnson johnson connection investigation janssen remicade contracting practice violate federal antitrust law company produce document information responsive civil investigative demand october certain united states service member family bring complaint number pharmaceutical medical device company include johnson johnson certain subsidiary united states district court district columbia allege defendant violate united states antiterrorism act complaint allege defendant provide fund terrorist organization sale practice pursuant pharmaceutical medical device contract iraqi ministry health july district court dismiss complaint january united states court appeal district columbia circuit reverse district court decision october separate putative class action file actelion pharmaceutical ltd actelion pharmaceutical inc actelion clinical research inc collectively actelion united states district court district maryland united states district court district columbia complaints allege actelion violate state federal antitrust unfair competition law allegedly refuse supply generic pharmaceutical manufacturer sample tracleer tracleer subject risk evaluation mitigation strategy require food drug administration impose restriction distribution product january plaintiff dismiss district columbia case file consolidated complaint united states district court district maryland october court grant actelion motion dismiss amend complaint april united states court appeals fourth circuit reverse remand discovery ongoing december janssen biotech inc janssen oncology inc janssen research development llc johnson johnson collectively janssen serve qui tam complaint file behalf united states states district columbia complaint file december united states district court northern district california allege janssen violate federal false claim act state law provide pricing information zytiga government connection direct government sale governmentfunde drug reimbursement program time federal state government decline intervene case transfer united states district court district new jersey janssen motion dismiss deny december class action antitrust complaint file janssen ireland janssen johnson johnson united states district court northern district california complaint allege janssen violate federal state antitrust consumer protection law agree exclusivity provision agreement gilead concern development marketing combination antiretroviral therapy cart treat hiv complaint allege gilead enter similar agreement bristolmyers squibb japan tobacco march court grant deny defendant motion dismiss plaintiff file amend complaint april defendant move dismiss amend complaint july court grant deny renew motion dismiss december insurance company payer file individual optout complaint contain allegation similar original complaint discovery ongoing october innovative health llc file complaint biosense webster inc bwi united states district court middle district california complaint allege certain bwis business practice contractual term violate antitrust law united states state california restricting competition sale high density mapping catheter ultrasound catheter january bwi file motion dismiss complaint august court grant deny bwis motion dismiss december bwi file motion summary judgment trial set april november johnson johnson receive demand indemnification pfizer inc pursuant stock asset purchase agreement company pfizer november johnson johnson inc receive demand indemnification sanofi consumer health inc pursuant asset purchase agreement johnson johnson inc sanofi january johnson johnson receive demand indemnification boehringer ingelheim pharmaceuticals inc pursuant asset purchase agreement company pfizer boehringer ingelheim notices seek indemnification legal claim relate overthecounter zantac ranitidine product plaintiff underlie action allege zantac overthecounter ranitidine medication contain unsafe level ndma nnitrosodimethylamine cause andor cause cancer patient product seek injunctive monetary relief october fortis advisor llc fortis capacity representative stockholder auris health inc auris file complaint johnson johnson ethicon inc certain name officer employee collectively ethicon court chancery state delaware complaint allege breach contract fraud cause action ethicon connection ethicon acquisition auris complaint seek damage relief december court grant deny defendant motion dismiss certain cause action claim individual defendant dismiss beginning multiple putative class action file state federal court california florida new york new jersey johnson johnson entities allege violation state consumer fraud statute base nondisclosure allege benzene contamination certain neutrogena aveeno sunscreen product affirmative promotion product safe case allege strict liability manufacture defect failure warn claim assert name plaintiff suffer unspecified injury result allege exposure benzene judicial panel multidistrict litigation consolidate pende action product liability case case pende new jersey state court united states district court southern district florida fort lauderdale division october company reach agreement principle settlement nationwide class encompass claim consolidated action subject approval florida federal court december plaintiff consolidate action file motion preliminary approval nationwide class settlement johnson johnson subsequently substitute johnson johnson consumer inc jjci company defendant cost recovery contribution action bring occidental chemical corporation june united states district court district new jersey relate cleanup section low passaic river new jersey johnson johnson subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund comparable state local foreign law primary relief seek cost past andor future remediation restructure fiscal second quarter company announce plan implement series action global supply chain intend focus resource increase investment critical capability technology solution necessary manufacture supply product portfolio enhance agility drive growth global supply chain action include expand use strategic collaboration bolster initiative reduce complexity improve costcompetitiveness enhance capability optimize supply chain network fiscal year company record pretax charge billion include follow line consolidate statement earning billion restructuring billion income expense billion cost product sell total project cost approximately billion record restructure announce follow table additional detail restructure program total company expect global supply chain action generate approximately billion billion annual pretax cost saving substantially deliver end program set complete end company expect record pretax restructuring charge approximately billion billion year period activity cost associate network optimization exit cost accelerate depreciation amortization follow table summarize severance charge associate spending initiative fiscal year end asset write severance total offssale dollar millions reserve balance december activity reserve balance january current year activity charge cash settlement settle non cash reserve balance january cash outlay severance expect substantially pay year accordance company plan local law include project expense salary employee support initiative consulting expense company continuously reevaluate severance reserve relate restructuring timing payment plan release associate longerterm project company believe exist severance reserve sufficient cover global supply chain plan give period action place company continue assess adjustment necessary additional amount probable estimable report independent register public accounting firm board director shareholders johnson johnson opinions financial statement internal control financial reporting audit accompany consolidated balance sheet johnson johnson subsidiaries company january january relate consolidated statement earning comprehensive income equity cash flow fiscal year period end january include related note collectively refer consolidated financial statement audit company internal control financial reporting january base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso opinion consolidated financial statement refer present fairly material respect financial position company january january result operation cash flow fiscal year period end january conformity accounting principle generally accept united states america opinion company maintain material respect effective internal control financial reporting january base criterion establish internal control integrate framework issue coso basis opinion company management responsible consolidated financial statement maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company consolidate financial statement company internal control financial reporting base audits public accounting firm register public company accounting oversight board united states pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audits accordance standard pcaob standard require plan perform audits obtain reasonable assurance consolidated financial statement free material misstatement error fraud effective internal control financial reporting maintain material respect audits consolidated financial statement include perform procedure assess risk material misstatement consolidated financial statement error fraud perform procedure respond risk procedure include examine test basis evidence amount disclosure consolidated financial statement audits include evaluate accounting principle significant estimate management evaluate overall presentation consolidate financial statement audit internal control financial reporting include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk audits include perform procedure consider necessary circumstance believe audits provide reasonable basis opinion definition limitation internal control financial reporting company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition assets company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company iii provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deterioratecritical audit matter critical audit matter communicate matter arise current period audit consolidated financial statement communicate require communicate audit committee relate account disclosure material consolidated financial statement involve especially challenge subjective complex judgment communication critical audit matter alter way opinion consolidated financial statement take communicate critical audit matter provide separate opinion critical audit matter account disclosure relate pharmaceutical rebate reserve manage care medicare medicaid describe note consolidated financial statement company recognize revenue product sale obligation term contract customer satisfy rebate discount provide customer account variable consideration record reduction sale liability rebate discount recognize accrue rebate return promotion consolidate balance sheet significant portion liability relate rebate sale pharmaceutical good primarily manage care medicare medicaid program amount billion january significant rebate program include manage care medicare medicaid rebate program rebate discount estimate management base contractual term historical experience patient outcome trend analysis project market condition pharmaceutical market principal consideration determination perform procedure relate pharmaceutical rebate reserve manage care medicare medicaid critical audit matter significant judgment management significant measurement uncertainty involve develop reserve high degree auditor judgment subjectivity audit effort perform procedure evaluate assumption relate contractual term historical experience patient outcome trend analysis project market condition pharmaceutical market addressing matter involve perform procedure evaluate audit evidence connection form overall opinion consolidated financial statement procedure include testing effectiveness control relate pharmaceutical rebate reserve manage care medicare medicaid include control assumption estimate rebate procedure include develop independent estimate rebate utilize party information price market condition pharmaceutical market term specific rebate program historical experience trend analysis actual rebate claim pay testing rebate claim process company include evaluate claim consistency contractual mandate term company rebate arrangement iii compare independent estimate management estimate litigation contingency talc describe note consolidated financial statement company record accrual loss contingency associate legal matter include talc probable liability incur loss reasonably estimate extent adverse award judgment verdict render company management record accrual loss determine probable reasonably estimate matter management unable estimate possible loss range loss amount accrue amount accrue legal contingency result complex series judgment future event uncertainty rely heavily estimate assumption include time relate payment ability estimate judgment affect factor include thing damage seek proceeding unsubstantiated indeterminate scientific legal discovery commence complete proceeding early stage matter present legal uncertainty significant fact dispute procedural jurisdictional issue uncertainty unpredictability number potential claim ability achieve comprehensive multiparty settlement complexity relate crossclaim counterclaim andor numerous party involve management continue believe company strong legal ground contest talc verdict appeal notwithstanding management confidence safety company talc product certain circumstance company settle case october johnson johnson consumer inc old jjci whollyowne subsidiary johnson johnson implement corporate restructuring create subsidiary ltl management llc ltl solely responsible talcrelate liability subsidiary new jjci responsible remain business old jjci ltl file voluntary petition seek relief chapter bankruptcy code result ltl bankruptcy case court enter temporary restraining order stay litigation ltl old jjci november north carolina bankruptcy court confirm scope stay issue preliminary injunction prohibiting enjoin commencement prosecution talcrelate claim ltl old jjci new jjci johnson johnson corporate affiliate identify retailer insurance company certain party claimant file motion dismiss ltl bankruptcy case court commence hearing february motion dismiss extend company agree provide funding ltl payment amount bankruptcy court determine owe ltl establishment billion trust furtherance purpose company establish reserve approximately billion connection aforementione trust party able reach aresolution matter relate talc certain amount scenario recently refer testimony ltl bankruptcy proceeding company unable estimate possible loss range loss accrue principal consideration determination perform procedure relate talc litigation critical audit matter significant judgment management assess likelihood loss incur determine reasonable estimate loss range loss future exist talc claim turn lead high degree auditor judgment subjectivity effort perform procedure evaluate management assessment loss contingency associate litigation address matter involve perform procedure evaluate audit evidence connection form overall opinion consolidated financial statement procedure include testing effectiveness control relate management evaluation talc litigation include control determine loss probable loss reasonably estimate financial statement disclosure procedure include gain understanding company process accounting report talc litigation discuss status significant know actual potential litigation ongoing ltl bankruptcy proceeding company inhouse legal counsel external counsel deem necessary iii obtain evaluate letter audit inquiry internal external legal counsel significant litigation evaluate reasonableness management assessment unfavorable outcome reasonably possible probable reasonably estimable evaluate sufficiency company litigation contingency disclosure litigation opioid describe note consolidated financial statement company record accrual loss contingency associate legal matter include opioid probable liability incur loss reasonably estimate extent adverse award judgment verdict render company management record accrual loss determine probable reasonably estimate matter management unable estimate possible loss range loss amount accrue amount accrue legal contingency result complex series judgment future event uncertainty rely heavily estimate assumption include time relate payment ability estimate judgment affect factor include thing damage seek proceeding unsubstantiated indeterminate matter present legal uncertainty significant fact dispute procedural jurisdictional issue uncertainty unpredictability number potential claim ability achieve comprehensive multiparty settlement complexity relate crossclaim counterclaim andor numerous party involve company name numerous lawsuit bring certain state local government include tribal government relate opioid matter october company announce propose agreement principle include company pay billion settlement matter october company agree contribute additional billion allin settlement resolve opioid lawsuit file future claim state city county tribal government total billion july company announce term agreement settle state subdivision claim finalize depend level participation party term provide period time state elect participate agreement period subdivision participate state optin subdivision optin period expire january company retain right optout agreement late february sole discretion insufficient participation principal consideration determination perform procedure relate opioid litigation critical audit matter significant judgment management determine reasonable estimate range loss agreement settle opioids litigation turn lead high degree auditor judgment subjectivity effort perform procedure evaluate management assessment loss contingency associate litigation address matter involve perform procedure evaluate audit evidence connection form overall opinion consolidated financial statement procedure include testing effectiveness control relate management evaluation opioid litigation include control determine loss probable loss reasonably estimate financial statement disclosure procedure include gain understanding company process accounting reporting opioid litigation discuss status significant know actual potential litigation ongoing settlement negotiation company inhouse legal counsel external counsel deem necessary iii obtain evaluate letter audit inquiry internal external legal counsel significant litigation evaluate reasonableness management assessment unfavorable outcome reasonably possible probable reasonably estimable evaluate sufficiency company litigation contingency disclosure pricewaterhousecooper llp florham park new jerseyfebruary serve company auditor able determine specific year begin serve auditor company management report internal control financial reporting section sarbanesoxley act management require assess effectiveness company internal control financial reporting end fiscal year report base assessment company internal control financial report effective management company responsible establish maintain adequate internal control financial reporting company internal control financial reporting design provide reasonable assurance reliability company financial reporting preparation external financial statement accordance generally accept accounting principle internal control financial reporting matter design inherent limitation internal control financial reporting determine effective provide reasonable assurance respect financial statement preparation prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate company management assess effectiveness company internal control financial reporting january make assessment company criterion establish committee sponsor organization treadway commission coso internal controlintegrate framework criterion area control environment risk assessment control activity information communication monitoring company assessment include extensive documenting evaluating testing design operating effectiveness internal control financial reporting base company process assessment describe management conclude january companys internal control financial report effective effectiveness company internal control financial reporting january audit pricewaterhousecooper llp independent register public accounting firm state report appear duato joseph wolk joaquin duato joseph wolk director executive vice president chief financial officer chief executive officer shareholder return performance graph set forth line graph compare cumulative total shareholder return company common stock period year year end january cumulative total return standard poor stock index standard poors pharmaceutical index standard poors healthcare equipment index graph table assume invest december december company common stock standard poor stock index standard poors pharmaceutical index standard poor healthcare equipment index dividend reinveste year shareholder return performance indices johnson johnson index pharmaceutical index healthcare equipment index year shareholder return performance indices johnson johnson index pharmaceutical index healthcare equipment index item change disagreement accountant account financial disclosure applicable item control procedure disclosure control procedure end period cover report company evaluate effectiveness design operation disclosure control procedure company disclosure control procedure design ensure information require disclose company report file submit exchange act record process summarize report time period specify sec rule form disclosure control procedure include limitation control procedure design ensure information require disclose company report file submit exchange act accumulate communicate company management include principal executive principal financial officer person perform similar function appropriate allow timely decision require disclosure joaquin duato chief executive officer joseph wolk executive vice president chief financial officer review participate evaluation base evaluation messrs duato wolk conclude end period cover report company disclosure control procedure effective report internal control financial reporting information call item incorporate reference management report internal control financial reporting attestation internal control financial reporting include report independent register public accounting firm include item report change internal control financial reporting fiscal quarter end january change companys internal control financial reporting identify connection evaluation require rules exchange act materially affect reasonably likely materially affect company internal control financial reporting company experience material impact internal control financial reporting despite fact employee work remotely covid pandemic company proactively take action reevaluate refine financial reporting process additional monitoring control provide reasonable assurance financial result report accurately timely company continue monitor assess effectiveness design operation disclosure control procedure company implement multiyear enterprisewide initiative integrate simplify standardize process system human resource information technology procurement supply chain finance function enhancement support growth company financial share service capability standardize financial system initiative response identify deficiency weakness company internal control financial reporting response initiative company continue align streamline design operation financial control environment item information applicable item disclosure foreign jurisdiction prevent inspection applicable iii item director executive officer corporate governance information call item incorporate reference discussion audit committee caption item election director board committee material caption item election director applicable stock ownership section compliance delinquent section report proxy statement material caption executive officer registrant report company code business conduct cover employee include chief executive officer chief financial officer controller meet requirement sec rules promulgate section thesarbanesoxley act code business conduct available company website wwwjnjcomcode ofbusinessconduct copy available shareholder charge write request secretary company principal executive office substantive amendment code business conduct waiver code grant chief executive officer chief financial officer controller post company website wwwinvestorjnjcomgovcfm business day retain website year addition company adopt code business conduct ethic member board director executive officer code business conduct ethic member board director executive officer available company website wwwinvestorjnjcomgovboardconductcfm copy available shareholder charge write request secretary company principal executive office substantive amendment code waiver code grant member board director executive officer post company website wwwinvestorjnjcomgovcfm business day retain website year item executive compensation information call item incorporate reference material caption item election director director compensation item compensation benefit committee report compensation discussion analysis executive compensation table proxy statement material incorporate reference material caption compensation benefit committee report proxy statement shall deem furnish file report shall deem incorporate reference filing security act amend securities exchange act amend result furnish extent company specifically incorporate reference item security ownership certain beneficial owner management relate stockholder matter information call item incorporate reference material caption item stock ownership section compliance proxy statement note common stock stock option plan stock compensation agreement note consolidated financial statement item report equity compensation plan information follow table provide certain information january concern share company common stock issue exist equity compensation plan number security weighted issue average exercise exercise price number security outstanding outstanding remain available option option future issuance equity plan category right right compensation plan equity compensation plan approve security holder equity compensation plan approve security holder total include category follow equity compensation plan approve company shareholder longterm incentive plan longterm incentive plan column exclude share reflect column number security issue exercise outstanding option right longterm incentive plan expire april option restrict share grant subsequent date longterm incentive plan item certain relationship relate transaction director independence information call item incorporate reference material caption item election director director independence relate person transaction proxy statement item principal accountant fee service information call item incorporate reference material caption item ratification appointment independent register public accounting firm proxy statementpart item exhibit financial statement schedule follow document file report financial statement consolidate balance sheet end fiscal year consolidated statement earning fiscal year consolidate statement comprehensive income fiscal year consolidated statement equity fiscal year consolidated statement cash flow fiscal year note consolidated financial statement report independent register public accounting firm schedule omit applicable require information include financial statement note exhibit require file item regulation information call item incorporate reference exhibit index report item summary registrant voluntarily include summary information require item company elect include summary information signature pursuant requirement section securities exchange act registrant duly cause report sign behalf undersigned thereunto duly authorize johnson johnson registrant date february duato duato director chief executive officer pursuant requirement securities exchange act report sign follow person behalf registrant capacity date indicate signature title date duato director february duato chief executive officer principal executive officer chief financial officer wolk february wolk principal financial officer controller chief accounting officer decker february decker principal accounting officer gorsky executive chairman board director february gorsky director beckerle february beckerle director davis february davis director davis february davis director doudna february doudna signature title date hewson director february hewson joly director february joly mcclellan director february mcclellan director mulcahy february mulcahy director prince february prince director washington february washington director weinberger february weinberger west director february west director williams february williams exhibit indexreg exhibit table description item exhibit restate certificate incorporation effective february incorporate reference exhibit registrant annual report fiscal year end january certificate amendment certificate incorporation johnson johnson effective april incorporate reference exhibit registrant form current report file april iii bylaw company amend effective june incorporate reference exhibit registrant form current report file june request securities exchange commission registrant furnish copy instrument define right holder longterm debt registrant description security register pursuant section security exchange act incorporate reference exhibit registrant form current report file august longterm incentive plan incorporate reference exhibit registrant registration statement file file form stock option certificate longterm incentive plan incorporate reference exhibit registrant form current report file january longterm incentive plan incorporate reference appendix registrant proxy statement file march form stock option certificate restrict share unit certificate performance share unit certificate longterm incentive plan incorporate reference